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With an ever-increasing number of vaccines on the market, making the right choices, both in terms of vaccine 
effectiveness and budget planning, has become increasingly important. In order to find the ideal balance between 
cost and quality of (i.e. providing the best possible protection to those who benefit the most in a given population), 
it is essential to first assess all available evidence before introducing a new vaccine to a national immunisation 
programme (NIP).  
The vaccine recommendation process should always be guided by a standardised and transparent assessment of 
available evidence. The recommendation process also needs to take into account the risks and benefits of the 
evaluated vaccine (‘context-free’ factors, e.g. vaccine effectiveness and safety) as well as local cultural values and 
preferences on vaccination (‘context-specific’ factors). In the majority of industrialised countries, national vaccine 
recommendations are developed by so-called national technical advisory groups (NITAGs) [1]. A NITAG is an 
independent expert advisory committee, providing ‘evidence-based recommendations to the Ministry of Health 
(MoH), policymakers and programme managers to guide policies and formulate strategies’ [2]. However, the role 
and tasks of NITAGs in the decision-making processes can differ considerably from country to country.  
During the ‘First international workshop on procedures for the development of evidence-based recommendations’ 
in Berlin in 2010 [3], a working group of international experts involved in vaccine decision-making processes 
discussed the values of international cooperation in the development of evidence-based vaccine recommendations 
and how it could be organised. It was pointed out, for example, that NITAGs in several countries conducted 
systematic reviews of the same body of evidence and that this duplication of efforts could be avoided by sharing 
reviews and putting them in the public domain. International cooperation in this area, the conference participants 
agreed, should ‘aim at the optimal utilisation of existing resources and the support of the NITAGs in the labor-
intensive preparation for evidence-based recommendations’. As a first step leading to international cooperation, the 
structures and modes of practice of the various NITAGs should be explored.  
In a 2013 survey conducted as part of the VENICE II project, Nohynek et al. explored key characteristics of 
NITAGs in EU/EEA Member States [4]. Twenty-two (85%) of the 27 responding European countries indicated that 
they had a NITAG in place. Ten NITAGs stated they had a framework for the development of NIP vaccine 
recommendations. However, the study collected no detailed framework information, e.g. whether NITAGs conduct 
systematic literature reviews or use results from mathematical modelling in the decision-making processes.  
This report describes and summarises the national processes for vaccine policymaking currently implemented, the 
roles of the Member States’ NITAGs and – if applicable – details of the national frameworks, with the aim to assess 
NITAG collaboration in Europe.  
Objectives 
The aim of this report is to identify and summarise current practices/frameworks established by NITAGs (or expert 
groups if no NITAG is in place) involved in the development of national vaccination recommendations in EU/EEA 
Member States. The rationale was to gain a better understanding of the different decision-making processes in 
each country and explore the potential for synergy and resource sharing between European NITAGs/expert groups, 
while also identifying potential barriers and limits to collaboration.  
The findings of this report are supplemented by results from a systematic literature review on methodologies/ 
frameworks used by WHO SAGE (Strategic Advisory Group of Experts) and a number of NITAGs in Europe and 
North America.  
Information collected by this survey is intended to inform a ‘roadmap for improving data, methodology and 
resource sharing between NITAGs in Europe’, which, if requested by ECDC, will be developed within the VENICE III 
project. 
Specific objectives of this document are: 
 to collect additional basic characteristics from NITAGs/expert groups in EU/EEA Member States, building on 
information which was collected during the previous NITAG survey in 2013; 
 to explore in more detail current practices and, if applicable, framework characteristics of EU/EEA Member 
States’ NITAGs/expert groups; 
 to explore the opinions of NITAGs/expert groups on the potential of, or limitations to, collaboration and 













 to conduct a systematic literature review on publications that describe current NITAG methodologies 
and/frameworks for decision-making processes for vaccine recommendations in Europe, North America and 
for WHO SAGE.  
Methodology 
NITAG survey of EU Member States and EEA countries 
The survey was designed as a follow-up and supplement of the NITAG survey conducted as part of the VENICE II 
project in March 2013 [4]. The VENICE gatekeepers in 27 EU Member States and the three EEA countries were 
asked to name, and provide contact details of, an expert in their respective countries who was involved in the 
decision-making process for national vaccine recommendations. Ideally, this person should be a member of the 
NITAG (e.g. the NITAG chairperson) or a staff member of the NITAG executive secretariat. In countries without 
NITAGs, the VENICE gatekeeper was asked to provide the contact details of an expert involved in the development 
of national vaccine recommendations.  
A questionnaire was developed, sent for evaluation and feedback to the VENICE III consortium members, and 
pilot-tested by staff members of the executive secretariat of the German NITAG. Due to the short time frame of 
the project, a more extensive pilot study could not be conducted. On 4 February 2014, the finalised questionnaire 
(see Annex A) was emailed to the nominated contact persons.  
The questionnaire consisted of four sections:  
 General part, e.g.: What is the role of the NITAG in the recommendation process? Is a NITAG website 
available?  
 Vaccine recommendation process, e.g.: Does a framework/standard operating procedure exist for the 
development of a vaccine recommendation? What are the key criteria? Is a systematic literature review 
required?  
 Potential for collaboration between NITAGs in the vaccine recommendation process, e.g.: What 
areas/aspects lend themselves to collaboration? 
 Open section, e.g.: Is there any other important information necessary to better understand the decision-
making process for vaccines? 
Completed questionnaires were sent back to the Robert Koch Institute, assessed for completeness and consistency. 
If there were unclear answers or remaining questions, a follow-up telephone interview was scheduled. Requests 
for minor clarifications were sent by email.  
Questionnaire Sections 1 and 2, as well as parts of Section 3, were analysed quantitatively to obtain aggregated 
results which describe key characteristics of NITAGs/expert groups in Europe. The remaining data retrieved from 
Section 3 and, if applicable, answers from Section 4 were analysed qualitatively. To protect confidentiality, 
qualitative answers were kept anonymous. Based on information from Sections 1 and 2 as well as data from the 
previous NITAG survey by Nohynek et al. [4], a profile (key characteristics) was created for each country. The 
country profiles were then sent to the respective survey respondents for final validation. 
Systematic literature review on methodologies/frameworks 
of NITAGs in Europe, North America, and WHO SAGE 
Literature search and study selection 
A systematic literature review to identify publications on methodologies/frameworks of NITAGs in Europe, North 
America and WHO SAGE was conducted on 6 March 2014, using MEDLINE, Global Health, EMBASE and the Health 
Technology Assessment Database.  
The following search strategy was used: 
#1 NITAG 
#2 National Immunization Technical Advisory Group 
#3 1 OR 2 
#4 National Immunization Technical Advisory Groups 
#5 3 OR 4 
#6 NIP 
#7 National Immunization Programme 












#9 5 OR 8 
#10 Vaccination 
#11 9 AND 10 
 
Restrictions: year of publication: 1990 – 6 March 2014 
Species: Human 
Snowballing sampling was used to identify additional publications and assessed the methodology/framework 
references provided by the interviewees in the NITAG survey. 
To be eligible for inclusion, the publication had to meet the following inclusion criteria: 1) the publication describes 
the methodology or framework of a NITAG or expert group involved in the vaccine decision-making process in 
Europe or North America or describes the methodology or framework of WHO SAGE; 2) the publication was 
published after 1990.  
Publications that were solely describing the structure of the NITAG/expert group or WHO SAGE were not included. 
Titles and abstracts were screened independently by two reviewers. Potentially eligible publications were reviewed 















Responses to the NITAG survey of EU/EEA Member States  
By 30 April 2014, 28/30 (93%) countries had responded to the questionnaire. Hungary and Luxemburg did not 
participate in the survey. Liechtenstein had to be excluded from the survey because the country – not having its 
own NITAG or expert group – adopts NITAG recommendations without further assessment from Switzerland.  
For Cyprus, only data from Section 3 (‘Potential for resource collaboration between NITAGs in the vaccine 
recommendation process’) were included in the results section. The Cyprus NITAG was discontinued in 2013. 
Cyprus plans to establish a new NITAG by 2016; in the meantime, an ad hoc committee assumes all NITAG 
functions. No country profile was created for Cyprus because the new terms of reference for the future NITAG 
have not been finalised and data on the temporary committee would skew the analysis.  
Follow-up or clarification questions were addressed to 26 countries; 17 (63%) countries were scheduled for an 
additional telephone interview, eight (30%) countries were contacted through email. For the remaining country, no 
follow-up interview could be scheduled. No follow-up questions arose for one country. 
General characteristics and NITAG functions 
All 26 participating countries stated that they have a NITAG or expert group involved in the national vaccine 
recommendation process; 21 (81%) of them designated themselves as NITAGs. The number of NITAG or expert 
group members ranged from 7 in Iceland to 35 in Belgium. Table 1 shows further general characteristics of the 
NITAGs or expert groups. 





Years since NITAG/expert group has been established:   
 < 5 years 5 19 
 5–20 years 12 46 
 > 20 years 9 35 
   
NITAG/expert group members have to declare potential conflicts of interest 20 77 
   
NITAG/expert group chair is:   
 Appointed by ministry of health or other/subordinate institution 20 77 
 Selected by NITAG/expert group members  5 19 
 No official chair 1 4 
   
NITAG/expert group has voting members from:   
 National public health institute (or equivalent) 15 58 
 Ministry of health 13 50 
 Neither ministry of health nor national public health institute (or equivalent) 5 19 
 
Table 2 describes the professional expertise represented in NITAGs and expert groups. Information is based on 
Nohynek et al. [4] and this survey. 






Epidemiology 25 96 
Paediatrics 24 92 
Clinical medicine 22 85 
Public health 21 81 
Vaccinology 21 81 
Immunology 20 77 
Microbiology (incl. virology) 17 65 
University faculty/various disease specialists  6 23 
Health economics 5 19 
General practice  5 19 
Regulatory authority on medicines 3 12 
Evidence-based medicine/systematic reviews 2 8 

















School health medicine 2 8 
Social sciences 2 8 
Ethics 1 4 
Health insurance system 1 4 
Lawyer 1 4 
Lay members 1 4 
Transmission modelling 1 4 
Pharmaceutical company1 1 4 
‘Well-baby clinics’ 1 4 
1 Representative from the Association of Pharmaceutical Companies 
 
Seventeen (65%) NITAGs/expert groups have an executive secretariat or administrative office. The number of full-
time staff in these offices ranged from no full-time staff to a maximum of 3.5 persons. Twenty (77%) 
NITAGs/expert groups indicated that they have additional persons/institutes scientifically supporting the 
NITAG/expert group. Those persons belonged to national public health institutes, other federal institutions (e.g. 
medicine agencies), universities, or were external (disease) specialists/experts.  
Eleven (42%) NITAGs or expert groups stated that they owned a website. Four countries provide online materials 
in English: while the websites in the United Kingdom and Malta offer comprehensive NITAG-specific material, the 
other two countries offer translations in three areas: a NITAG description (n=1), background material (e.g. 
recommendations) (n=2), and miscellaneous materials (e.g. advisory reports) (n=1). 
The NITAGs’ or expert groups’ role in the decision-making process of a national vaccine introduction is summarised 
in Table 3. 
Table 3: Role of NITAGs/expert groups (n=26) in the decision-making process for the introduction of 






NITAG/expert group advises:   
 Ministry of health 16 62 
 National public health institute (or equivalent)  9 35 
 No advisory function 1 4 
   
Final decision to introduce a new vaccine to the national vaccination schedule/programme:    
 Ministry of health 12 46 
 Ministry of health in combination with other stakeholders (e.g. regional authorities 
and/or Ministry of finance) 
9 35 
 Parliament or government 3 12 
 NITAG* 2 8 
   
Funding scheme for vaccinations in the national immunisation schedule   
 Tax-funded 19 73 
 Mixed (tax-funded and social insurance) 4 15 
 Social insurance 3 12 
* Includes one country where the ministry of health is obliged to introduce the vaccine if it is recommended by the NITAG, 
provided it is also cost-effective. 
It should be noted that information on the national funding scheme sometimes only applies to ‘mandatory 
vaccinations’, as opposed to ‘recommended vaccinations’, which are treated as out-of-pocket medical expenses, 
e.g. in Poland. Recommended vaccinations (to be paid out-of-pocket) include, but are not limited to, travel 
vaccinations. See also Annex B. 
Frameworks/processes for evidence assessment 
Of the 26 countries that participated, 20 (77%) indicated that the NITAG uses a systematic approach (e.g. 
framework or standard operating procedure). Of those 20 systematic approaches, 13 (65%) contained a fixed list 
of key criteria (e.g. disease burden in the country, etc.) that need to be addressed. The key elements and key 
criteria of those systematic approaches are listed in Annex B.  
Fifteen (58%) countries indicated that they are required to use systematic literature reviews to answer key 
questions before they can issue national vaccine recommendation. Although ten countries declared that they are 
not required to do so, they stated that systematic literature reviews are optional and are often conducted if 













systematic reviews, gave the following reasons for not conducting literature reviews: ‘too much work’ (n=4), ‘lack 
of funding/resources’ (n=5), ‘invited experts in the field already have a good overview of the published literature 
and can therefore select the most relevant publications’ (n=1), and ‘lack of local epidemiological data’ (n=1). Table 
4 further describes elements of the vaccine recommendation process in the surveyed countries. 







NITAG/expert group usually uses:   
 Self-conducted systematic reviews and published systematic reviews by others (e.g. 
Cochrane Collaboration) 
17 65 
 Only published systematic reviews by others  8 31 
 No reviews 1 4 
   
Mathematical modelling considered as part of the recommendation development process (e.g. 
transmission modelling) 
18 69 
Mathematical modelling is:   
 Outsourced (e.g. national public health institute or similar institute) 15 58 
 Developed within NITAG/NITAG executive secretariat 8 31 
 Experiences exist with adopting existing models to own local setting 7 27 
   
Health economic evaluations considered as part of the recommendation process (e.g. cost-
effectiveness studies) 
20 77 
Level at which the economic evaluation is considered:   
 NITAG/expert group 16 62 
 Ministry of health or government, parliament or ministry of finance (or similar) 14 54 
 Economic assessment contains cost-effectiveness threshold 5 19 
 Cost-effectiveness threshold is final/decisive criterion 2 8 
Of the 17 NITAGs/expert groups that conduct systematic reviews, 17 (100%) use peer-reviewed data; nine (53%), 
also use unpublished/non-peer reviewed data in addition to peer-reviewed data. Five (31%) of those 17 countries 
apply quality appraisal tools for individual studies (e.g. Critical Appraisal Skills Programme (CASP), Cochrane risk of 
bias tool) or a system to grade the quality of the body of evidence (e.g. the GRADE approach (Grading of 
Recommendations, Assessment, Development and Evaluation)). Tools or systems named were GRADE (n=4), CASP 
(n=2) and the Cochrane Risk of Bias Tool (n=1).  
Of the 25 NITAGs or expert groups that utilise systematic reviews conducted by other groups, three (12%) stated 
that they assess the methodological quality of the review using a tool (AMSTAR: n=2; PRISMA: n=1). Eight 
NITAGs declared that they outsource or are allowed to outsource systematic reviews to a third party (e.g. an 
institution or private company); of those, five said that they require an evidence assessment to be performed, and 
five stated that the contract allows them to share the systematic review with other parties, e.g. foreign health 
agencies. 
Table 5 provides information on the number of NITAGs/expert groups that usually publish an explanatory 
background paper outlining the rationale behind a positive or negative recommendation decision. It has to be 
noted that the respondents’ answers can refer to both peer-reviewed or non-peer reviewed online publications, e.g. 
on the NITAG’s/expert group’s own website. 
Table 5: NITAGs/expert groups (n=26) that usually publish an explanatory background outlining the 
rationale behind a positive or negative recommendation decision 
 Countries (n) Percentage (%) 
Background paper published with decision rationale 13 50 
If yes, the document contains…   
References to used literature 9 69 
Narrative summary  8 62 
Detailed results of systematic reviews including meta-analysis 6 46 
Other materials 6 46 
Comprehensive background report (including all items above) 2 15 
Country profiles 
A listing of the general characteristics and specifics of the vaccine recommendation process by country can be 












Potential for collaboration 
Of the 27 countries that participated, 25 (93%) thought that there is ‘potential for a collaboration/resource-sharing 
between NITAGs to support the individual country’s process of developing vaccination recommendations’. Two 
countries believed that there was no potential. Asked for reasons, one country stated ‘lack of resources’, the other 
country pointed out that ‘the committee is just for recommendation to the Minister of Health’. This could not be 
explored further because no follow-up phone interview could be scheduled. 
When asked in which areas collaboration or resource sharing would be most productive, five (20%) of the 25 
countries named systematic literature reviews, and 14 (56%) mentioned collaborating in context-free aspects like 
vaccine effectiveness, vaccine efficacy or vaccine safety. Of the total of 19 (76%) countries that saw potential for 
collaboration in the area of systematic literature reviews and/or context-free aspects in particular, twelve had 
indicated in Section 2 of the questionnaire that they were required to perform systematic reviews during the 
vaccine recommendation process; of those 12, ten conduct their own reviews. 
Nineteen (76%) countries thought it would be beneficial to also collaborate in context-specific aspects. One 
country stated that ‘there is always a value to also share the context-specific aspects’, another that ‘context-
specific material may be illustrative of possible interpretations, assessments and recommendations’. Cost-
effectiveness and/or mathematical modelling were mentioned by 15 countries, and disease burden assessment by 
11 countries. It was suggested that ‘mathematical models and cost-effectiveness models could be shared in order 
to be adapted to every specific country’ and that ‘burden assessment templates and mathematical modelling 
templates [should be shared] in which specific assumptions and country data could be introduced’.  
One country mentioned that it was ‘unsure about context- and country-specific aspects’ and another pointed out 
that ‘context-specific aspects like cost-effectiveness modelling can be difficult as other institutes needed to be 
included in the collaboration’. 
Asked about minimum requirements for joint systematic reviews, mathematical modelling and/or economic models, 
18 countries (72%) favoured agreed methodologies and written guidelines. However, while most countries only 
mentioned that there should be agreed methodologies, some respondents provided more detail: ‘Collaborating 
NITAGs should have the possibility to give input in the beginning of the process, e.g. which outcomes should be 
considered in the review or inclusion/exclusion criteria of studies’; also, a common methodology should include ‘e.g. 
a search strategy, paper selection, and exclusion criteria of publications’, make ‘use of the same tools, e.g. GRADE, 
AMSTAR, etc.’ and should ‘guarantee high quality of the work, for better comparability and to make the review 
process more transparent’. Finally, one country mentioned that there should also be ‘a plan for peer 
review/publication’ of those collaborative/shared systematic reviews. 
Regarding barriers and limitations to collaboration, responses fell into three different categories: 
a) Lack of funding and/or lack of (personnel) resources and/or lack of available expertise (n=10) 
Most of the countries expressing this barrier/limitation were small countries and/or countries with fewer resources.  
b) Possible language barriers and cultural differences (n=5) 
Cultural differences and their different values and preferences may lead to a different assessment of available 
evidence and thus to different recommendations: ‘This [vaccination recommendations including assessments of 
several sub-questions, each of them with their own value judgments], in our opinion, not only precludes grading of 
the recommendation, it also means that any assessment can only partially rely on a systematic review or an 
economic model. Although it will be stimulating and useful to participate in any such collaborative effort, that effort 
will cover only part of the assessment.’  
c) Structural concerns (n=16)  
Countries mentioned either limiting differences in the countries’ healthcare systems/vaccine delivery structures and 
disease burden/epidemiological situation, or differences among countries regarding the respective role of the 
NITAG and NITAG (working) structures. Concern was expressed ‘when the collaboration exceeds the technical level’ 
or that ‘tasks of the vaccination recommendation process can be in different institutions; close collaboration 
[among those intra-country institutions] would be necessary which is often yet not present’. Furthermore, 
‘NITAGs/MoH put different value on the methodological requirements in the process of developing NITAG 
recommendations due to differences in the available resources but also due to different consequences of the 
NITAG recommendations. … [If the NITAG decision] triggers automatically a coverage decision by health 
insurances, there is much more of a need to apply rigorous methodologies and be transparent as much as 
possible.’  
Another point raised in the questionnaires was that NITAGs may not always work on the same topic(s): ‘countries 
might be in a different process, one is considering a vaccination while another one is considering another one. 
However, this should still not hinder collaboration. When a country is considering to assess [a specific] vaccination, 













Finally, the survey assessed the countries’ interests in sharing information on current NITAG activities and output; 
respondents were asked to rate the helpfulness of sharing information on a scale from 1 (not necessary at all) to 5 
(very helpful). The Figure below depicts the median score for each of the three sub-questions. Answers for sub-
question 1 ranged between 2 and 5; for sub-questions 2 and 3 answers ranged between 1 and 5.  
Figure: Rated level of interest in NITAG activities or output, as expressed by NITAG’s/expert groups 
(n=26); median rating scores 
 
Systematic literature review regarding 
methodologies/frameworks of NITAGs in Europe, North 
America and WHO SAGE 
The first search retrieved 299 publications. De-duplication and title screening reduced the number to 
31 publications. Applying the snowballing technique generated an additional 20 potentially eligible publications. 
After a full text screening of a total of 51 publications, eight publications were eligible in accordance with the 
inclusion criteria. They were supplemented with six additional non-peer reviewed publications which also met the 
inclusion criteria and were provided by the respondents of the NITAG survey. A list of excluded publications can be 
found in Annex C. 
The identified publications of methodologies/frameworks refer to nine European and the two North American 
countries; one publication covers WHO SAGE: 
Europe 
Denmark Health Technology Assessment. Toolbox. Available from: 
https://sundhedsstyrelsen.dk/en/health/quality-and-guidelines/centre-for-health-technology-
assessment  
Finland Nohynek H. The Finnish decision-making process to recommend a new vaccine: From vaccine 
research to vaccination policy. J Public Health 2008;16:275-80. 
 Systematic approach for development of national vaccine recommendations [in Finnish]. 
Available from: http://www.thl.fi/fi_FI/web/rokottajankasikirja-fi/kansallinen-
rokotusasiantuntijaryhma  
…systematic reviews jointly conducted or outsourced by a 
group of European NITAGs?
…information from the various European NITAGs on vaccine 
recommendations/assessments that are currently in progress?
…information on the priorities of European NITAGs on vaccination 




2 3 4 5













Germany Standing Committee on Vaccination. Standard operating procedures of the German Standing 
Committee on Vaccination (STIKO) for the development of vaccination recommendations. Version 
1.0. Available from: http://www.stiko.de/en  
Italy Ministero della Salute. Piano Nazionale Prevenzione Vaccinale (PNPV). 2012-2014 [in Italian]. 
Available from: http://www.salute.gov.it/imgs/C_17_pubblicazioni_1721_allegato.pdf  
Portugal Diário da República. Portaria no 243/2013, 11/04/2013; DR, 2a série, no 78, 22/04 [in Portugese]. 
Available from: http://dre.pt/pdfgratis2s/2013/04/2S078A0000S00.pdf  
Spain Grupo de trabajo criterios 2011, de la ponencia de programa y registro de vacunaciones criterios 
de evaluación para fundamentar modificationes en el programa de vacunación en españa. 
comisión de salud pública del consejo interterritorial del sistema nacional de salud. Ministerio de 
Sanidad, Política, Social e Igualdad. 2011. [in Spanish]. Available from: 
http://www.msssi.gob.es/ciudadanos/proteccionSalud/vacunaciones/docs/Criterios_ProgramaVac
unas.pdf  
Sweden Socialstyrelsen. Modell för framtagande av underlag till regeringen inför beslut om nationella 
vaccinationsprogram. 2013. [in Swedish]. Available from: 
http://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/19243/2013-11-9.pdf  
Switzerland Masserey Spicher V. The Federal Vaccination Commission in Switzerland: An officially appointed 
independent commission ensuring evidence-based recommendations and transparent procedures. 
Vaccine 2010;28S:A48-A53. 
The Netherlands Houweling H, Verweij M, Ruitenberg EJ, on behalf of the National Immunisation Programme 
Review Committee of the Health Council of the Netherlands. Criteria for inclusion of vaccinations 
in public programmes. Vaccine 2010;28:2924-31. 
 Health Council of the Netherlands. The future of the National Immunisation Programme: towards 
a programme for all age groups. Report nr. 2007/02E. The Hague: Health Council of the 
Netherlands, 2007. Available from: http://gr.nl/sites/default/files/200702E_0.pdf  




Canada Ismail SJ, Langley JM, Harris TM, Warshawsky BF, Desai S, FarhangMehr M. Canada’s National 
Advisory Committee on Immunization (NACI): Evidence-based decision-making on vaccines and 
immunization. Vaccine 2010;28(Suppl.1):A58-63. 
 National Advisory Committee on Immunization (NACI). Evidence-based recommendations for 
immunization – methods of the National Advisory Committee on Immunization. An Advisory 
Committee Statement (ACS). Can Commun Dis Rep 2009;35(ACS-1):1-10. 
 Erickson LJ, De Wals P, Farand L. An analytical framework for immunization programs in Canada. 
Vaccine 2005;23:2470-76. 
United States  Ahmed F, Temte JL, Campos-Outcalt D, Schünemann HJ, for the ACIP Evidence Based 
Recommendations Work Group (EBRWG). Methods for developing evidence-based 
recommendations by the Advisory Committee on Immunization Practices (ACIP) of the U.S. 
Centers for Disease Control and Prevention. Vaccine 2011;29:9171-76. 
WHO SAGE 
WHO SAGE  Duclos P, Durrheim DN, Reingold AL, Bhutta ZA, Vannice K, Rees H. Developing evidence-based 
immunization recommendations and GRADE. Vaccine 2012;31:12-19. 
 
Six of the 12 countries had their framework published in a peer-reviewed journal, as did WHO SAGE. Two of these 
countries also published additional framework information on their NITAG-related websites. The remaining seven 
frameworks were only published on websites associated with the NITAG/expert group or government. The Finnish 
peer-reviewed framework publication used a practical example (Haemophilus influenzae type b, seven-valent 
pneumococcal conjugate and human papilloma virus) to illustrate the decision-making process. Information 
included in the published frameworks for Italy, Portugal, Spain and Sweden was not used because the documents 
were not available in English. 
Publications of the non-surveyed countries Switzerland, Canada and the United States, and also of WHO SAGE, 













outcomes. In Switzerland for example, the following outcomes are considered (in descending importance): 
mortality, hospitalisations, overall morbidity, epidemic potential, and equity and disability-adjusted life years 
(DALYs) or quality-adjusted life years (QALYs). The decision-making process is based on a process previously 
established in Quebec, Canada (described in Eriksen et al.), and later adapted to the Swiss situation. The Canadian 
NITAG has its own system to assess the quality of evidence (‘Schema for ranking individual study design’ and 
‘Quality (internal validity) rating’), followed by a ‘Synthesis of the body of evidence’ conducted by the respective 
NITAG Working Group. By contrast, WHO SAGE and the US NITAG require the use of GRADE in their frameworks 
as a grading system to assess the quality of the body of evidence. The Canadian NITAG uses a system of six 
criteria (good/fair evidence for/against recommendation of a vaccination, conflicting evidence, insufficient evidence) 
while the US NITAG assigns three recommendation categories (vaccination recommendation applies to all persons 
in an age or risk group; vaccination is up to individual clinical decisions; no recommendation/unsolved issue) to 













Discussion and conclusions 
The survey gathered information on 28 of the 30 EU and EEA countries, thereby allowing for a detailed and 
representative inventory of NITAGs and expert groups involved in the vaccine recommendation process. All but two 
of the participating countries have a NITAG or expert group in place. Of those two countries without NITAGs, one 
is currently restructuring its health system (which led to the discontinuation of its NITAG in 2013; a new NITAG will 
be implemented by 2016), while the other one directly implements the NITAG recommendations of its bigger 
neighbouring country.  
This survey of NITAGs shows a wide variety of structures, outlines the diverse roles NITAGs play within the 
decision-making process, and offer some insights in the resources available to NITAGs or expert groups. Although 
77% of the NITAGs claim that they use a systematic approach, e.g. a framework or standard operating procedure, 
an analysis of the key elements and key criteria of these frameworks showed that the range of approaches used by 
the various NITAGs within those systematic approaches is large and differs between countries. Only nine (45%) of 
the countries with a framework chose to publish it, and only two of those countries published their framework in a 
peer-reviewed journal, offering the added advantage of easy access via Pubmed. The remaining frameworks were 
published on websites associated with the NITAG/expert group or government, which makes access rather difficult. 
To complicate matters even further, four of those seven frameworks were only available in the local language.  
Nearly all (96%) NITAGs/expert groups in our survey indicated the use of systematic reviews. While some NITAGs 
only user their own systematic reviews, others also used reviews by a third party (e.g. Cochrane Collaboration) or 
relied on both options. The use of a tool or grading system to assess the quality of evidence is not very common: 
five respondents claimed they used grading systems for single studies, while three declared they used such tools to 
evaluate bodies of evidence. Only eight (31%) of the surveyed countries are entitled to outsource systematic 
reviews. Of those who do, five are allowed to share the results with other parties.  
Health economic assessments were part of most vaccine recommendation processes (n=20; 77%). Five countries 
indicated to have a cost-effectiveness threshold. However, only two countries use exceeding this threshold as a 
criterion against a vaccine. Mathematical modelling as part of the recommendation process was conducted in 
18 (69%) countries. Seven countries have adapted models from third countries to their local situation. However, 
the fact that more countries cited health economic assessments than mathematical modelling (mathematical 
modelling is indispensable for cost-effectiveness studies) might indicate that respondents interpreted the two terms 
different from their intended meaning. 
Nearly all NITAGs and expert groups (93%) believed that the development of evidence-based vaccination 
recommendations had a potential for collaboration and resource sharing. A high percentage (76%) of NITAGs 
wanted to collaborate in the field of systematic reviews, covering both context-free and context-specific aspects. 
The context-free areas mentioned were vaccine effectiveness, vaccine efficacy, vaccine safety; context-specific 
areas included cost-effectiveness, mathematical modelling and the assessment of disease burden. With regard to 
joint systematic reviews, 72% favoured agreed methodologies and written guidelines as a minimum requirement. 
A small number of countries suggested a number of concrete requirements (probably based on national 
prerequisites in their systematic approaches), including predefinitions for search strategies, inclusion/exclusion 
criteria for publications, and the application of tools or grading systems (e.g. GRADE, AMSTAR) to make the review 
process more transparent.  
Regarding barriers and limitations for collaboration, responses could be grouped into three categories: lack of 
resources and expertise in the country (concerns voiced to a large degree from smaller countries or countries with 
less resources), possible language barriers and cultural differences, and barriers due to structural concerns, either 
based on structural differences in the NITAGs’ role in the decision making process, framework requirements and 
working structures or based on differences in the countries’ health care systems, vaccine delivery structures and 
epidemiological situations/disease burdens. 
In what could be seen as a potential first step towards collaboration, respondents generally considered it very 
helpful to receive information on recent output from other NITAGs/expert groups. They showed great interest in an 
institutional platform organising joint systematic reviews, which would either be conducted by a group of EU/EEA 
NITAGs or outsourced by them; other topics for joint activities could include information on vaccine 
recommendations and vaccine assessments performed by the various NITAGs/expert groups in the EU, as well as 
information on NITAGs’/expert groups’ priorities for vaccine recommendations that needed to be dealt with in the 
near future. Information on the last two points has already been collected under Work Package 4 of this project. 
Information collected in this survey provides baseline data which make it possible to further explore 
a) collaboration at the individual NITAG/expert group level (see information provided in the country profiles), and 
b) collaboration at the EU level by establishing structures for broader resource-sharing, e.g. providing an inter-













practical issues, e.g. data protection, a code of conduct for considering unpublished data, concrete guidelines for 
systematic reviews, and a decision where such an inter-institutional platform would be hosted.  
This survey could therefore serve as a starting point for developing a roadmap for improved data, methodology 
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Appendix A. Questionnaire 
I. General part 
 
1. Does your country have a National Immunization Technical Advisory Group (NITAG)? 
☐ Yes ☐ No (please go to question 3) 
 
2. If a NITAG is in place:  
2.1 Are experts from the following institutions voting-members of your NITAG?  
Ministry of Health    ☐ Yes  ☐ No  
National Public Health Institute/equivalent  ☐ Yes  ☐ No 
     ☐ Not applicable 
2.2 How /by whom is the NITAG chair selected or appointed? 
Answer:  
2.3 Does your NITAG have an Executive Secretariat/administrative office? 
☐ Yes ☐ No  
2.3.1 If yes: How many full-time staff are on the secretariat?  
Answer:  
2.3.2 Are there additional persons that scientifically support the NITAG in its work?  
☐ Yes ☐ No 
2.3.2.1 If yes: From which institutions?  
Answer:  
 
3. If no NITAG is in place:  
3.1 Is any other expert group involved in the decision-making process?  
☐ Yes ☐ No (please go to question 3.1.2) 
3.1.1 If yes: Of whom does the expert group consist? Who choses/appoints them? How are they chosen? Is it a standing group or do 
the experts change depending on the topic/question? 
Answer:  
3.1.2 If no: Who is the key decision-making driver in your country? 
Answer:  
 
4. Could you briefly explain the decision making process of a national vaccine introduction in your country by answering the following questions: 
4.1 Which institutions /expert groups are involved (e.g. NITAG, Ministry of Health, Parliament) and in what order?  
Answer:  
4.2 Which institution/ministry or the like is the NITAG (or expert group making the national vaccine recommendation) attached to/part 
of?  
Answer:  
4.3 Who does the NITAG (or expert group making the national vaccine recommendation) advise (e.g. ministry of health)?  
Answer:  
4.4 Who takes the final decision on the introduction of a new vaccine in the national vaccine schedule (e.g. ministry of health, ministry 
of finance, parliament)? 
Answer:  
4.5 Who pays for the vaccination adopted in the national immunisation schedule of your country? (e.g. public-funded program, 
reimbursement etc.)  
Answer:  
 
5. Does your NITAG or the expert group making the national vaccine recommendations has/have a website? 
☐ Yes ☐ No (please go to question 6) 
5.1 If yes: Please provide the address: 
Answer:  
5.2 If yes: Does you provide English translations of NITAG-specific material on that website? 
 ☐ Yes ☐ No (please go to question 6) 
  5.2.1 If yes: Which parts are translated? 
  ☐ NITAG description ☐ Background materials (e.g. recommendations)  
☐ All   ☐ Other:  




II. Vaccine recommendation process 
 
7. Does your NITAG/the expert group developing the national vaccine recommendations use a systematic approach (in the sense of a framework or 
standard operating procedure) that is adhered to during the development of a vaccine recommendation? 
☐ Yes ☐ No (please go to question 8) 
7.1 If yes: Could you briefly describe this framework? What are the key elements? 
Answer:  
7.2 If yes: Is that systematic approach set out in writing? 
☐ Yes ☐ No (please go to question 7.3) 
  7.2.1 If yes: Has it been published? 
  ☐ Yes  ☐ No 
  7.2.2 If yes: Can you provide us with the document or the URL? 
  ☐ Yes  ☐ No 
  7.2.3 If yes: Document is sent per email  ☐ Yes  ☐ No 












7.3 If yes: Does it contain a fixed list of key criteria (e.g. disease burden in the country etc.) that needs to be addressed? 
☐ Yes ☐ No (please go to question 8) 
7.3.1 If yes: What are they? 
Answer:  
 
8. Is your NITAG or the expert group required to use systematic literature reviews to answer key questions for a national vaccine recommendation? 
☐ Yes (please go to question 8.4) ☐ No (please go to question 8.1) 
8.1 If no: What procedure do you use instead?  
Answer:  
 
8.2 If no: What are the reasons that you do not conduct/use systematic reviews?  
☐ Too much work   
☐ Language barriers   
☐ Limited/no access to certain journals 
☐ Lack of funding/resources   
☐ Other:   
8.3 Would you consider it helpful to be provided with a systematic review for the respective topic by an independent body? 
☐ Yes  ☐ No (please go to question 9) 
8.4 If yes: Do you usually use published systematic reviews (conducted by others such as the Cochrane Collaboration) or do you 
conduct the systematic literature reviews yourself?   
☐ own product (please go to question 8.4.1) 
☐ conducted by others (please go to question 8.4.4)  
☐ both (please explain):  
8.4.1 If NITAG/NITAG Secretariat conducts own reviews: Who conducts them? (e.g. NITAG members, secretariat staff or 
outsourced)? 
Answer:  
8.4.2 If NITAG/NITAG Secretariat conducts own reviews: Do you only include peer-reviewed evidence or also unpublished 
data in your reviews?  
☐ only peer-reviewed ☐ peer-reviewed and unpublished/non-peer reviewed 
8.4.2.1 If unpublished/non-peer-review data: Where is the data usually coming from? (e.g. from industry or 
European Public Assessment Reports)?  
Answer:  
8.4.3 If NITAG/NITAG Secretariat conducts own reviews: Do you apply quality appraisal tools (QATs) for individual studies 
or systems to grade the quality of the body of evidence (e.g. GRADE)?  
☐ Yes ☐ No (please go to question 9)  
8.4.3.1 If yes: Which one do you usually apply? 
Answer:  
8.4.4 If you use reviews conducted by others (e.g. published in peer-reviewed journals or outsourced): Do you assess 
the methodological quality of the review? 
  ☐ Yes ☐ No (please go to question 8.5) 
8.4.4.1 If yes: How is it assessed (e.g. AMSTAR)? 
Answer: 
8.5 Do you outsource systematic reviews to a third party (e.g. institution, private company)? 
☐ Yes ☐ No (please go to question 9) 
8.5.1 If yes: Is there a guideline that has to be followed when you outsource reviews (in the sense: are there criteria that 
have to be fulfilled in the final product)?  
☐ Yes ☐ No (please go to question 8.5.2) 
8.5.1 If yes: What are they? 
Answer:  
8.5.2 If yes: Do you require an evidence grading system to be used to assess the quality of the body of gathered literature 
(e.g. GRADE)? 
☐ Yes ☐ No (please go to question 8.5.3) 
8.5.2.1 If yes: Which one? 
Answer:  
8.5.3 If yes: Does the contract (usually) allow you to share the systematic review with other parties, e.g. foreign national 
health agencies? 
☐ Yes ☐ No 
 
9. Do you include results of own/outsourced/published mathematical modelling (e.g. transmission modelling) in your vaccine recommendation 
process if applicable? 
☐ Yes ☐ No (please go to question 10) 
 9.1. If yes: Do you usually develop such models yourself or outsource such work?  
☐ Own models  ☐ Outsource (please go to question 10) 
9.2. If own models: Do you have experiences in adopting existing models from other countries to your own local setting (e.g. through 
a collaborative effort)?  
☐ Yes  ☐ No 
 
10. Are at any stage health economic evaluations (e.g. cost-effectiveness studies) part of the vaccine recommendation process? 
☐ Yes ☐ No (please go to question 11) 
10.1 If yes: At what decision level of the vaccine recommendation process are health economic assessments considered (e.g. within the 
NITAG, later at Ministry of Health or Parliament)? 
Answer:  
10.2 If yes: Does the economic assessment contain a cost-effectiveness threshold that should not be exceeded (e.g. 30,000 € per 
avoided QALY)? 
☐ Yes  ☐ No (please go to question 11) 
10.2.1 If yes: Is the excess of the cost-effectiveness threshold a final/definite criterion against the vaccine introduction? 














11. After a decision has been made regarding the positive or negative recommendation of a vaccine: Do you usually publish (peer-reviewed or 
online, e.g. own website) a background paper with a decision rationale? 
☐ Yes ☐ No (please go to question 12) 
11.1 If yes: What does it include? 
☐ Narrative summary 
☐ Detailed results of systematic reviews including meta-analysis   
☐ References of used literature 
☐ Other:  
 
III. Potential for resource collaboration between NITAGs in the vaccine recommendation process 
 
12. Do you think there is potential for collaboration/resource-sharing between NITAGs to support the individual country’s process of developing 
vaccination recommendations? 
☐ Yes ☐ No (please go to question 12.2) 
12.1 If yes: In which areas/aspects of the vaccination recommendation development process (e.g. context-free aspects (such as review 
of vaccine efficacy/effectiveness data) or context-specific aspects (such as country-specific modelling of cost-effectiveness, mathematical 
modelling or disease burden assessment))? 
Answer:  
12.1.1 If the interviewee believes that joint systematic reviews or joint use/development of 
mathematical/economic models are possible: What would be minimum requirements for a collaboration in conducting 
such work (e.g. agreed guidelines, methodologies)? 
Answer:  
 12.2 If no: For what reasons? 
Answer:  
 
13. What barriers or limitations do you see in general for collaboration between NITAGs?  
Answer:  
 
14. Would you consider an institutional platform as helpful that would host: 
14.1 systematic reviews jointly conducted or outsourced by a group of European NITAGs? 
  ☐ 1  ☐ 2  ☐ 3  ☐ 4  ☐ 5 
(not necessary at all)       (very helpful) 
14.2 information on vaccine recommendations/assessments currently in progress of the different European NITAGs? 
 ☐ 1  ☐ 2  ☐ 3  ☐ 4  ☐ 5 
(not necessary at all)       (very helpful) 
14.3 information on European NITAGs’ priorities for vaccine recommendations that need to be dealt with? 
 ☐ 1  ☐ 2  ☐ 3  ☐ 4  ☐ 5 
(not necessary at all)       (very helpful) 
 
IV Supplemental information 
 
15. Is there any other important information that can be shared with us to better understand the immunization decision-making process in your 
country and potential modes of NITAG collaboration? 
Answer:  












Appendix B. Validated country profiles 
AUSTRIA (validated) As of 30 April 2014 
General facts 
Name of recommending body Nationales Impfgremium (NIG)  
English:  
National Vaccination Committee 
Self-designation as National Immunization 
Technical Advisory Group (NITAG) 
Yes 
Contact National Vaccination Committee 
Prof. Ursula Wiedermann, NITAG chair 
Year established 2011 (previous committee: 1984–2010) 
Website No  
Website material in English Not applicable 
NITAG or /expert group executive 
secretariat/administrative office 
No 
NITAG or expert group receives 
(additional) scientific support from: 
If applicable, representatives of topic-related specialties 
Number of NITAG or expert group 
members 
10 
NITAG or expert group chair is 
elected/appointed by 
Ministry of Health  
Voting-member composition Clinicians, epidemiologists, immunologists, paediatricians, public health experts, 
vaccinology experts, virologists/microbiologists/infectiologists 
Voting member(s) from Ministry of Health Yes 
Declaration of conflict of interest Yes 
Number of meetings per year 3–5 
Meetings open to public No 
Minutes published online No 
NITAG or expert group advises: Ministry of Health 
Final decision-maker for vaccine 
introduction in the national programme 
Ministry of Health after negotiation with the Ministry of Finance, the Federal States 
Governments and social insurance  
Funding scheme for vaccinations in the 
national immunisation schedule 
Mixed (4/6 Ministry of Health, 1/6 Federal State Governments, 1/6 social 
insurance) 
 
Vaccine recommendation process 
Systematic approach 
NITAG or expert group uses systematic 
approach for the development of national 
vaccine recommendations  
Yes 
Key elements of the systematic approach • Formulation of question: PICO approach for interventions, flexible approach for 
other cases 
• Systematic literature research (definition of inclusion/exclusion criteria, data bases 
and/or other sources) 
• Data/study selection 
• Assessment of the data/studies: modified GRADE for interventions, individually 
adapted/chosen criteria for other cases 
Fixed list of key criteria which need to be 
addressed during  the development 
process  
Yes 
List of criteria Primary criteria: 
• Availability of vaccine 
• Vaccines of special public health importance  
• Epidemiology 
• Data on efficacy and safety of the vaccine 
Secondary criteria: 
• Opportunities and risks of vaccination programme 
• Expected acceptability 
• Compatibility with existing vaccination schedule 
• Vaccines in the existing vaccination schedule 
Systematic approach published No 
URL Not applicable 
Systematic literature review 
Recommendation development process 
requires systematic literature review  
Yes 
Systematic literature review is conducted 















Vaccine recommendation process 
Data source(s) Peer-reviewed  
Unpublished/non-peer reviewed (European Public Assessment reports, EMA 
authorisation reports) 
Evidence assessment performed with 
tool/system 
Yes 
Name of applied risk of bias tool(s) (e.g. 
CASP) or grading system(s) (e.g. GRADE) 
Modified GRADE (e.g. observational studies start as ‘high quality’) 
Systematic literature review is/can be 
outsourced by the NITAG or expert group 
No 
Evidence assessment required to be 
performed 
Not applicable 
Contract allows sharing of systematic 
review with other parties 
Not applicable 
Systematic literature reviews conducted or 
published by others (e.g. Cochrane 
Collaboration) are/can be considered by 
NITAG or expert group/Executive 
Secretariat 
Yes 
Methodological quality of the review 
assessed by NITAG or expert 
group/Executive Secretariat using 
tool/assessment system 
Yes 
Name of tool(s) (e.g. AMSTAR) PRISMA guidelines 
Mathematical modelling (e.g. transmission modelling) 
Recommendation development process 
includes consideration of results from 
mathematical modelling 
Yes 
Developed by NITAG 
Outsourced 
Experience with adopting existing models 
from other countries to own setting 
No 
Health economic evaluations (e.g. cost-effectiveness studies) 
Recommendation development process 
includes consideration of results from 
health economic evaluations 
Yes 
Contains cost-effectiveness threshold No 
Cost-effectiveness threshold (e.g. per 
QALY) 
Not applicable 
Cost-effectiveness threshold definite 
criterion for/against vaccine introduction 
Not applicable 
Tender system in place  Yes 
 National/regional/local National 
Decision communication 
Rationale for vaccine recommendation 
published 
Yes 














BELGIUM (validated)   As of 30 April 2014 
General facts 
Name of recommending body Hoge Gezondheidsraad – Conseil Supérieur de la Santé  
English:  
Superior Health Council 
Self-designation as National Immunisation 
Technical Advisory Group (NITAG) 
Yes 
Contact Superior Health Council 
Dr Veerle Mertens, Scientific Collaborator 
Year established 1991 
Website www.hgr-css.be 
Website material in English No 
NITAG or /expert group executive 
secretariat/administrative office 
Yes 
NITAG or expert group receives 
(additional) scientific support from:: 
Federal and regional institutions and universities 
Number of NITAG or expert group 
members 
35 
NITAG or expert group chair is 
elected/appointed by 
NITAG members 
Voting-member composition Clinicians, epidemiologists, health economists, immunologists, paediatricians, 
public health experts, vaccinology experts, virologists/microbiologists, general 
practitioner, school health medicine specialist, ‘well baby clinics’ specialist 
Voting member(s) from Ministry of Health Yes 
Declaration of conflict of interest Yes 
Number of meetings per year > 5 
Meetings open to public No 
Minutes published online No 
NITAG or expert group advises Ministry of Health/Social Affairs 
Final decision-maker for vaccine 
introduction in the national programme 
National Ministry of Health/Social Affairs and Regional Ministries of Health 
Funding scheme for vaccinations in the 
national immunisation schedule 
Mixed  
(children: tax-funded; adults: social insurances) 
 
Vaccine recommendation process 
Systematic approach 
NITAG or expert group uses systematic 
approach for the development of national 
vaccine recommendations  
No 
Key elements of the systematic approach Not applicable 
Fixed list of key criteria which need to be 
addressed during  the development 
process  
Not applicable 
List of criteria Not applicable 
Systematic approach published Not applicable 
URL Not applicable 
Systematic literature review 
Recommendation development process 
requires systematic literature review  
No 
Systematic literature review is conducted 
by the NITAG or expert group/Executive 
Secretariat itself 
Yes 
Data source(s) Peer-reviewed 
Unpublished/non-peer reviewed (country-specific surveillance data, hearing of 
vaccine companies) 
Evidence assessment performed with 
tool/system 
No 
Name of applied risk of bias tool(s) (e.g. 
CASP) or grading system(s) (e.g. GRADE) 
Not applicable 
Systematic literature review is/can be 
outsourced by the NITAG or expert group 
No 
Evidence assessment required to be 
performed 
Not applicable 
Contract allows sharing of systematic 














Vaccine recommendation process 
Systematic literature reviews conducted or 
published by others (e.g. Cochrane 
Collaboration) are/can be considered by 
NITAG or expert group/Executive 
Secretariat 
Yes 
Methodological quality of the review 
assessed by NITAG or expert 
group/Executive Secretariat using 
tool/assessment system 
No 
Name of tool(s) (e.g. AMSTAR) Not applicable 
Mathematical modelling (e.g. transmission modelling) 
Recommendation development process 
includes consideration of results from 
mathematical modelling 
No 
Developed by Not applicable 
Experience with adopting existing models 
from other countries to own setting 
Not applicable 
Health economic evaluations (e.g. cost-effectiveness studies) 
Recommendation development process 
includes consideration of results from 
health economic evaluations 
Not required – asked for at the Ministry-of-Health level (performed by Belgian 
Health Care Knowledge Center) 
Contains cost-effectiveness threshold No 
Cost-effectiveness threshold (e.g. per 
QALY) 
Not applicable 
Cost-effectiveness threshold definite 
criterion for/against vaccine introduction 
Not applicable 
Tender system in place  Yes 
National/regional/local Regional 
Decision communication 
Rationale for vaccine recommendation 
published 
Yes 
Rationale includes References of used literature 













BULGARIA (validated)  30 April 2014 
General facts 
Name of recommending body Експертен съвет по надзор на заразните болести, имунопрофилактика и 
противоепидемичен контрол   
English:  
Expert Committee for Communicable Disease Surveillance, Immunoprophylaxis and 
Control 
Self-designation as National Immunisation 
Technical Advisory Group (NITAG) 
No 
Contact Dr. Radosveta Filipova, Expert Committee member, country EPI manager 
Year established 2002 
Website No 
Website material in English Not applicable 
NITAG or /expert group executive 
secretariat/administrative office 
No 
NITAG or expert group receives 
(additional) scientific support from:: 
No 
Number of NITAG or expert group 
members 
13 
NITAG or expert group chair is 
elected/appointed by 
Chair is the Deputy Minister of Health (member of the Expert Committee, but with 
no voting rights), Co-Chair is the Chief State Health Inspector  
Voting-member composition Clinicians, epidemiologists, paediatricians, vaccinology experts, 
virologists/microbiologists, lawyer 
Voting member(s) from Ministry of Health No 
Declaration of conflict of interest No 
Number of meetings per year 3–5 
Meetings open to public No 
Minutes published online No 
NITAG or expert group advises Ministry of Health 
Final decision-maker for vaccine 
introduction in the national programme 
Minister of Health 
Funding scheme for vaccinations in the 
national immunisation schedule 
Tax-funded 
 
Vaccine recommendation process 
Systematic approach 
NITAG or expert group uses systematic 
approach for the development of national 
vaccine recommendations  
No 
Key elements of the systematic approach Not applicable 
Fixed list of key criteria which need to be 
addressed during  the development 
process  
Not applicable 
List of criteria Not applicable 
Systematic approach published Not applicable 
URL Not applicable 
Systematic literature review 
Recommendation development process 
requires systematic literature review  
No 
Systematic literature review is conducted 
by the NITAG or expert group/Executive 
Secretariat itself 
No 
Data source(s) Not applicable 
Evidence assessment performed with 
tool/system 
Not applicable 
Name of applied risk of bias tool(s) (e.g. 
CASP) or grading system(s) (e.g. GRADE) 
Not applicable 
Systematic literature review is/can be 
outsourced by the NITAG or expert group 
No 
Evidence assessment required to be 
performed 
Not applicable 
Contract allows sharing of systematic 
review with other parties 
Not applicable 
Systematic literature reviews conducted or 
published by others (e.g. Cochrane 
Collaboration) are/can be considered by 















Vaccine recommendation process 
Methodological quality of the review 
assessed by NITAG or expert 
group/Executive Secretariat using 
tool/assessment system 
Not applicable 
Name of tool(s) (e.g. AMSTAR) Not applicable 
Mathematical modelling (e.g. transmission modelling) 
Recommendation development process 
includes consideration of results from 
mathematical modelling 
Yes 
Developed by expert group 
Outsourced 
Experience with adopting existing models 
from other countries to own setting 
No 
Health economic evaluations (e.g. cost-effectiveness studies) 
Recommendation development process 
includes consideration of results from 
health economic evaluations 
No 
Contains cost-effectiveness threshold Not applicable 
Cost-effectiveness threshold (e.g. per 
QALY) 
Not applicable 
Cost-effectiveness threshold definite 
criterion for/against vaccine introduction 
Not applicable 
Tender system in place  Yes (annual) 
 National/regional/local National 
Decision communication 
Rationale for vaccine recommendation 
published 
No 














CZECH REPUBLIC (validated)  As of 30 April 2014  
General facts 
Name of recommending body Národní imunizační komise (NIKO)  
English:  
National Immunisation Board 
Self-designation as National Immunisation 
Technical Advisory Group (NITAG) 
Yes 
Contact Vladimír Valenta, chief hygienic officer 
Year established 2010 
Website http://www.mzcr.cz/Verejne/obsah/cile-a-zamereni_1984_5.html 
Website material in English No 
NITAG or /expert group executive 
secretariat/administrative office 
No 
NITAG or expert group receives 
(additional) scientific support from: 
Czech Medical Association of JEP (Jan Evangelista Purkyně) and the Scientific 
Societies belonging to it, e.g. Vaccinological Society, Epidemiological and 
Microbiological Society, Society of Infectious Disease Specialists, Paediatric Society, 
General Practitioners Society, Czech Pneumological and Phthisiological Society, 
National Institute of Public Health, State Institute for Drug Control, Health Care 
Insurance Companies etc. 
Number of NITAG or expert group 
members 
11 
NITAG or expert group chair is 
elected/appointed by 
Ministry of Health 
Voting-member composition Clinicians, epidemiologists, immunologists, paediatricians, public health experts, 
vaccinology experts, general practitioners 
Voting member(s) from Ministry of Health Yes 
Declaration of conflict of interest Yes 
Number of meetings per year 3–5 
Meetings open to public No 
Minutes published online Yes 
NITAG or expert group advises Ministry of Health 
Final decision-maker for vaccine 
introduction in the national programme 
Parliament 
Funding scheme for vaccinations in the 
national immunisation schedule 
Mixed  
(Social insurances for mandatory vaccinations; Ministry of Health for extraordinary 
vaccinations – for example for selected risk groups in selected areas e.g. in case of 
floods or infectious diseases outbreaks) 
 
Vaccine recommendation process 
Systematic approach 
NITAG or expert group uses systematic 
approach for the development of national 
vaccine recommendations  
Yes 
Key elements of the systematic approach • Epidemiological situation 
• Safety of vaccination 
• Consultation with relevant specialties 
Fixed list of key criteria which need to be 
addressed during  the development 
process  
No 
List of criteria Not applicable 
Systematic approach published No 
URL Not applicable 
Systematic literature review 
Recommendation development process 
requires systematic literature review  
Yes 
Systematic literature review is conducted 
by NITAG or expert group/Executive 
Secretariat itself 
No 
Data source(s) Not applicable 
Evidence assessment performed with 
tool/system 
Not applicable 
Name of applied risk of bias tool(s) (e.g. 
CASP) or grading system(s) (e.g. GRADE) 
Not applicable 
Systematic literature review is/can be 
outsourced by the NITAG or expert group 
No 
Evidence assessment required to be 
performed 
Not applicable 
Contract allows sharing of systematic 














Vaccine recommendation process 
Systematic literature reviews conducted or 
published by others (e.g. Cochrane 
Collaboration) are/can be considered by 
NITAG or expert group/Executive 
Secretariat 
Yes 
Methodological quality of the review 
assessed by NITAG or expert 
group/Executive Secretariat using 
tool/assessment system 
No 
Name of tool(s) (e.g. AMSTAR) Not applicable 
Mathematical modelling (e.g. transmission modelling) 
Recommendation development process 
includes consideration of results from 
mathematical modelling 
No 
Developed by Not applicable 
Experience with adopting existing models 
from other countries to own setting 
Not applicable 
Health economic evaluations (e.g. cost-effectiveness studies) 
Recommendation development process 
includes consideration of results from 
health economic evaluations 
Yes 
Contains cost-effectiveness threshold No 
Cost-effectiveness threshold (e.g. per 
QALY) 
Not applicable 
Cost-effectiveness threshold definite 
criterion for/against vaccine introduction 
Not applicable 
Tender system in place  Yes 
 National/regional/local National 
Decision communication 
Rationale for vaccine recommendation 
published 
Yes 
Rationale includes Narrative summary 













DENMARK (validated)  As of 30 April 2014 
General facts 
Name of recommending body Sundhedsstyrelsens Vaccinationsudvalg  
English:  
The National Vaccine Committee 
Self-designation as National Immunisation 
Technical Advisory Group (NITAG) 
Yes 
Contact Dr Palle Valentiner-Branth, EPI manager and head of the national vaccine-
preventable diseases surveillance group, Statens Serum Institut 
Year established At least from 1980 
Website https://sundhedsstyrelsen.dk/da/sundhed/vaccination/vaccinationsudvalg 
Website material in English No 
NITAG or /expert group executive 
secretariat/administrative office 
Yes 
NITAG or expert group receives 
(additional) scientific support from: 
When necessary experts from relevant organisations such as infectious disease 
specialists, paediatricians, health economists 
Number of NITAG or expert group 
members 
14 
NITAG or expert group chair is 
elected/appointed by 
Danish Health and Medicines Authority 
Voting-member composition Clinicians, epidemiologists, immunologists, paediatricians, public health experts, 
vaccinology experts, representative from Association of pharmaceutical companies  
Voting member(s) from Ministry of Health No 
Declaration of conflict of interest Yes 
Number of meetings per year 2 
Meetings open to public No 
Minutes published online Yes 
NITAG or expert group advises Danish Health and Medicines Authority 
Final decision-maker for vaccine 
introduction in the national programme 
Parliament 
Funding scheme for vaccinations in the 
national immunisation schedule 
Tax-funded 
 
Vaccine recommendation process 
Systematic approach 
NITAG or expert group uses systematic 
approach for the development of national 
vaccine recommendations  
Yes – if a Medical Health Technology Assessment (MTA) is carried out (but no 
predefined criteria when to do an MTA) 
Key elements of the systematic approach For MTA: 
• Different sections of technology (methodology, e.g. a systematic literature review, 
efficacy of the vaccine, impact on morbidity on the population level after 
vaccination, side effects, interactions with other vaccines) 
• Perspectives of citizens and patients 
• Organisation (e.g. experiences from other countries who have used this vaccine, 
planning of the vaccination programme, number and timing of doses, catch-up 
programme, procurement of the vaccine) 
• Health economics 
Fixed list of key criteria which need to be 
addressed during  the development 
process  
No 
List of criteria Not applicable 
Systematic approach published Yes 
URL https://sundhedsstyrelsen.dk/en/health/quality-and-guidelines/centre-for-health-
technology-assessment 
Systematic literature review 
Recommendation development process 
requires systematic literature review  
Yes – if an MTA is carried out 
Systematic literature review is conducted 
by the NITAG or expert group/Executive 
Secretariat itself 
Yes 
Data source(s) Peer-reviewed 
Unpublished/non-peer reviewed (national surveillance data for estimate of disease 
burden) 
Evidence assessment performed with 
tool/system 
No 
Name of applied risk of bias tool(s) (e.g. 
CASP) or grading system(s) (e.g. GRADE) 
Not applicable 
Systematic literature review is/can be 
outsourced by the NITAG or expert group 













Vaccine recommendation process 
Evidence assessment required to be 
performed 
Yes 
Contract allows sharing of systematic 
review with other parties 
Yes 
Systematic literature reviews conducted or 
published by others (e.g. Cochrane 
Collaboration) are/can be considered by 
NITAG or expert group/Executive 
Secretariat 
Yes 
Methodological quality of the review 
assessed by NITAG or expert 
group/Executive Secretariat using 
tool/assessment system 
No 
Name of tool(s) (e.g. AMSTAR) Not applicable 
Mathematical modelling (e.g. transmission modelling) 
Recommendation development process 
includes consideration of results from 
mathematical modelling 
Yes 
Developed by NITAG 
Outsourced 
Experience with adopting existing models 
from other countries to own setting 
Yes 
Health economic evaluations (e.g. cost-effectiveness studies) 
Recommendation development process 
includes consideration of results from 
health economic evaluations 
Yes 
Contains cost-effectiveness threshold No 
Cost-effectiveness threshold (e.g. per 
QALY) 
Not applicable 
Cost-effectiveness threshold definite 
criterion for/against vaccine introduction 
Not applicable 
Tender system in place  Yes 
National/regional/local National 
Decision communication 
Rationale for vaccine recommendation 
published 
Yes 
Rationale includes Entire report is made public 
Including: 
• Narrative summary 
• Detailed results of systematic reviews including meta-analysis 













ESTONIA (validated)  As of 30 April 2014 
General facts 
Name of recommending body Immunoprofülaktika ekspertkomisjon 
English:  
Expert Committee on Immunoprophylaxis 
Self-designation as National Immunisation 
Technical Advisory Group (NITAG) 
No 
Contact Dr Martin Kadai, Expert Committee member 
Year established 2006 
Website No 
Website material in English Not applicable 
NITAG or /expert group executive 
secretariat/administrative office 
Yes 
NITAG or expert group receives 
(additional) scientific support from: 
Estonian Health Board 
Number of NITAG or expert group 
members 
15 
NITAG or expert group chair is 
elected/appointed by 
Minister of Social Affairs  
Voting-member composition Clinicians, epidemiologists, immunologists, paediatricians, public health experts, 
virologists/microbiologists, representatives from the Estonian Health Insurance 
Fund, State Agency of Medicine, Estonian Union for Child Welfare and Estonian 
Association of Family Doctors 
Voting member(s) from Ministry of Health Yes 
Declaration of conflict of interest Yes 
Number of meetings per year 3–5 
Meetings open to public No 
Minutes published online No 
NITAG or expert group advises Ministry of Social Affairs (incorporates Health) 
Final decision-maker for vaccine 
introduction in the national programme 
Ministry of Social Affairs, if additional financing is needed the Government 
Funding scheme for vaccinations in the 
national immunisation schedule 
Tax-funded 
 
Vaccine recommendation process 
Systematic approach 
NITAG or expert group uses systematic 
approach for the development of national 
vaccine recommendations  
Yes 
Key elements of the systematic approach 1. Disease burden; 
2. Vaccine effectiveness, efficacy and safety; 
3. Cost-effectiveness; 
4. Availability of alternative public health measures; 
5. Availability of financial resources; 
6. Acceptance and expectations of and adherence to vaccination.    
Fixed list of key criteria which need to be 
addressed during  the development 
process  
Yes 
List of criteria 1. Disease burden; 
2. Vaccine effectiveness, efficacy and safety; 
3. Cost-effectiveness; 
4. Availability of alternative public health measures; 
5. Availability of financial resources; 
6. Acceptance and expectations of and adherence to vaccination.    
Systematic approach published No 
URL Not applicable 
Systematic literature review 
Recommendation development process 
requires systematic literature review  
No 
Systematic literature review is conducted 
by the NITAG or expert group/Executive 
Secretariat itself 
No 
Data source(s) Not applicable 
Evidence assessment performed with 
tool/system 
Not applicable 
Name of applied risk of bias tool(s) (e.g. 
CASP) or grading system(s) (e.g. GRADE) 
Not applicable 
Systematic literature review is/can be 














Vaccine recommendation process 
Evidence assessment required to be 
performed 
Not applicable 
Contract allows sharing of systematic 
review with other parties 
Not applicable 
Systematic literature reviews conducted or 
published by others (e.g. Cochrane 
Collaboration) are/can be considered by 
NITAG or expert group/Executive 
Secretariat 
Yes 
Methodological quality of the review 
assessed by NITAG or expert 
group/Executive Secretariat using 
tool/assessment system 
No 
Name of tool(s) (e.g. AMSTAR) Not applicable 
Mathematical modelling (e.g. transmission modelling) 
Recommendation development process 
includes consideration of results from 
mathematical modelling 
Yes 
Developed by Estonian Health Board 
Outsourced 
Experience with adopting existing models 
from other countries to own setting 
Not applicable 
Health economic evaluations (e.g. cost-effectiveness studies) 
Recommendation development process 
includes consideration of results from 
health economic evaluations 
Yes 
Contains cost-effectiveness threshold No 
Cost-effectiveness threshold (e.g. per 
QALY) 
Not applicable 
Cost-effectiveness threshold definite 
criterion for/against vaccine introduction 
Not applicable 
Tender system in place  Yes 
 National/regional/local National 
Decision communication 
Rationale for vaccine recommendation 
published 
No 













FINLAND (validated)  As of 30 April 2014 
General facts 
Name of recommending body Kansallinen rokotusasiantuntijatyöryhmä (KRAR)  
English:  
National Vaccination Expert Working Group 
Self-designation as National Immunisation 
Technical Advisory Group (NITAG) 
Yes 
Contact Prof Matti Korppi, NITAG chair 
Dr Hanna Nohynek, NITAG secretary 
Year established 2001 
Website http://www.thl.fi/fi_FI/web/rokottajankasikirja-fi/kansallinen-
rokotusasiantuntijaryhma 
Website material in English No 
NITAG or /expert group executive 
secretariat/administrative office 
Yes 
NITAG or expert group receives 
(additional) scientific support from: 
National Institute for Health and Welfare (THL) 
Number of NITAG or expert group 
members 
13 
NITAG or expert group chair is 
elected/appointed by 
National Institute for Health and Welfare 
Voting-member composition Clinicians, epidemiologists, immunologists, paediatricians, public health experts, 
vaccinology experts, virologists/microbiologists 
Voting member(s) from Ministry of Health Yes 
Declaration of conflict of interest Yes 
Number of meetings per year 3–5 
Meetings open to public No 
Minutes published online No 
NITAG or expert group advises National Institute for Health and Welfare (that advises the Ministry of Health) 
Final decision-maker for vaccine 
introduction in the national programme 
Parliament after recommendation from Ministry of Finance as part of annual 
financial budget package for NIP immunisations 
Funding scheme for vaccinations in the 
national immunisation schedule 
Tax-funded 
 
Vaccine recommendation process 
Systematic approach 
NITAG or expert group uses systematic 
approach for the development of national 
vaccine recommendations  
Yes 
Key elements of the systematic approach 1. Considerable disease burden  
2. Vaccine safety on individual level  
3. Vaccine safety on population level  
4. Reasonable cost effectiveness 
Fixed list of key criteria which need to be 
addressed during  the development 
process  
Yes 
List of criteria 1. Considerable disease burden  
2. Vaccine safety on individual level  
3. Vaccine safety on population level  
4. Reasonable cost effectiveness 
Systematic approach published Yes 
URL http://www.thl.fi/fi_FI/web/rokottajankasikirja-fi/kansallinen-
rokotusasiantuntijaryhma 
Systematic literature review 
Recommendation development process 
requires systematic literature review  
Yes 
Systematic literature review is conducted 
by NITAG or expert group/Executive 
Secretariat itself 
Yes 
Data source(s) • Peer-reviewed 
• Unpublished/non-peer reviewed (own research, manufacturers, European 
Medicines Agency and Fimea reports) 
Evidence assessment performed with 
tool/system 
No 
Name of applied risk of bias tool(s) (e.g. 
CASP) or grading system(s) (e.g. GRADE) 
Not applicable 
Systematic literature review is/can be 














Vaccine recommendation process 
Evidence assessment required to be 
performed 
Not applicable 
Contract allows sharing of systematic 
review with other parties 
Not applicable 
Systematic literature reviews conducted or 
published by others (e.g. Cochrane 
Collaboration) are/can be considered by 
NITAG or expert group/Executive 
Secretariat 
Yes 
Methodological quality of the review 
assessed by NITAG or expert 
group/Executive Secretariat using 
tool/assessment system 
No 
Name of tool(s) (e.g. AMSTAR) Not applicable 
Mathematical modelling (e.g. transmission modelling) 
Recommendation development process 
includes consideration of results from 
mathematical modelling 
Yes 
Developed by National Institute for Health and Welfare 
Experience with adopting existing models 
from other countries to own setting 
No 
Health economic evaluations (e.g. cost-effectiveness studies) 
Recommendation development process 
includes consideration of results from 
health economic evaluations 
Yes 
Contains cost-effectiveness threshold Yes 
Cost-effectiveness threshold (e.g. per 
QALY) 
No formal absolute threshold 
Cost-effectiveness threshold definite 
criterion for/against vaccine introduction 
No 
Tender system in place  Yes 
 National/regional/local National 
Decision communication 
Rationale for vaccine recommendation 
published 
Yes 
Rationale includes • Narrative summary 
• Detailed results of systematic reviews including meta-analysis 
• References of used literature 














FRANCE (validated)   As of 30 April 2014 
General facts 
Name of recommending body Comité Technique des Vaccination  
English:  
Vaccine Technical Committee 
Self-designation as National Immunisation 
Technical Advisory Group (NITAG) 
Yes 
Contact Prof Daniel Floret, NITAG chair 
Corinne Le Goaster, NITAG Executive Secretariat 
Year established 1985 
Website www.hcsp.fr 
Website material in English No 
NITAG or /expert group executive 
secretariat/administrative office 
Yes 
NITAG or expert group receives 
(additional) scientific support from: 
Institut de veille sanitaire (French Institute for Public Health Surveillance), Agence 
Nationale de Sécurité des Médicaments 
Number of NITAG or expert group 
members 
17 
NITAG or expert group chair is 
elected/appointed by 
NITAG members 
Voting-member composition Clinicians, epidemiologists, health economists, immunologists, paediatricians, 
public health experts, social scientists, vaccinology experts, 
virologists/microbiologists 
Voting member(s) from Ministry of Health No 
Declaration of conflict of interest Yes 
Number of meetings per year > 5 
Meetings open to public No 
Minutes published online No 
NITAG or expert group advises Ministry of Health 
Final decision-maker for vaccine 
introduction in the national programme 
Ministry of Health 
Funding scheme for vaccinations in the 
national immunisation schedule 
Mixed (tax-funded and social insurance) 
 
Vaccine recommendation process 
Systematic approach 
NITAG or expert group uses systematic 
approach for the development of national 
vaccine recommendations  
No 
Key elements of the systematic approach Not applicable 
Fixed list of key criteria which need to be 
addressed during  the development 
process  
Not applicable 
List of criteria Not applicable 
Systematic approach published Not applicable 
URL Not applicable 
Systematic literature review 
Recommendation development process 
requires systematic literature review  
No 
Systematic literature review is conducted 
by the NITAG or expert group/Executive 
Secretariat itself 
Yes 
Data source(s) Peer-reviewed 
Evidence assessment performed with 
tool/system 
Yes 
Name of applied risk of bias tool(s) (e.g. 
CASP) or grading system(s) (e.g. GRADE) 
GRADE 
Systematic literature review is/can be 
outsourced by the NITAG or expert group 
Yes 
Evidence assessment required to be 
performed 
Yes 
Contract allows sharing of systematic 
review with other parties 
No 
Systematic literature reviews conducted or 
published by others (e.g. Cochrane 
Collaboration) are/can be considered by 















Vaccine recommendation process 
Methodological quality of the review 
assessed by NITAG or expert 
group/Executive Secretariat using 
tool/assessment system 
No 
Name of tool(s) (e.g. AMSTAR) Not applicable 
Mathematical modelling (e.g. transmission modelling) 
Recommendation development process 
includes consideration of results from 
mathematical modelling 
Yes 
Developed by NITAG 
Outsourced 
Experience with adopting existing models 
from other countries to own setting 
Yes 
Health economic evaluations (e.g. cost-effectiveness studies) 
Recommendation development process 
includes consideration of results from 
health economic evaluations 
Yes 
Contains cost-effectiveness threshold No 
Cost-effectiveness threshold (e.g. per 
QALY) 
Not applicable 
Cost-effectiveness threshold definite 
criterion for/against vaccine introduction 
Not applicable 
Tender system in place  Yes 
National/regional/local National 
Decision communication 
Rationale for vaccine recommendation 
published 
Yes 
Rationale includes • Detailed results of systematic reviews including meta-analysis 
• References of used literature 














GERMANY (validated)   As of 30 April 2014 
General facts 
Name of recommending body Ständige Impfkommission (STIKO)  
English:  
German Standing Committee on Vaccination 
Self-designation as National Immunisation 
Technical Advisory Group (NITAG) 
Yes 
Contact NITAG Executive Secretariat 
Year established 1972 
Website www.stiko.de/en 
Website material in English Yes 
NITAG or /expert group executive 
secretariat/administrative office 
Yes 
NITAG or expert group receives 
(additional) scientific support from: 
National Public Health Institute (Robert Koch Institute) 
Number of NITAG or expert group 
members 
12–18 
NITAG or expert group chair is 
elected/appointed by 
NITAG members 
Voting-member composition Clinicians, epidemiologists, immunologists, paediatricians, vaccinology experts, 
virologists/microbiologists, expert in evidence-based medicine 
Voting member(s) from Ministry of Health No 
Declaration of conflict of interest Yes 
Number of meetings per year ≥ 2 
Meetings open to public No 
Minutes published online Yes (since 2013) 
NITAG or expert group advises No advisory function. The STIKO recommendations serve as the basis for the  
• reimbursement decision (making the reimbursement of the respective vaccine 
compulsory for all statutory health insurances in Germany), and  
• official vaccination recommendations of the German federal states (which is 
needed for vaccines to be considered by the federal states’ vaccine injury 
compensation system)  
Final decision-maker for vaccine 
introduction in the national programme 
NITAG 
Funding scheme for vaccinations in the 
national immunisation schedule 
Social insurance 
 
Vaccine recommendation process 
Systematic approach 
NITAG or expert group uses systematic 
approach for the development of national 
vaccine recommendations  
Yes 
Key elements of the systematic approach 1. Prioritisation process of topic 
2. Identification of relevant questions, using PICO format 
3. Conduct of systematic reviews for each critical and important efficacy/safety 
outcome 
4. Application of GRADE for grading the quality of the body of evidence for 
efficacy/safety outcomes 
5. Address all other relevant questions according to a standard list of key criteria 
Fixed list of key criteria which need to be 
addressed during  the development 
process  
Yes 
List of criteria Questions related to: 
a) pathogen  
b) target disease  
c) vaccine characteristics  
d) immunisation strategy  
e) implementation of a vaccination recommendation 
Systematic approach published Yes 
URL www.stiko.de/en >> STIKO methodology 
Systematic literature review 
Recommendation development process 
requires systematic literature review  
Yes 
Systematic literature review is conducted 
by the NITAG or expert group/Executive 
Secretariat itself 
Yes 
Data source(s) Peer-reviewed 















Vaccine recommendation process 
Name of applied risk of bias tool(s) (e.g. 
CASP) or grading system(s) (e.g. GRADE) 
For RCTs: Cochrane risk of bias tool 
For observational studies: CASP tool  
For body of evidence: GRADE 
 
Systematic literature review is/can be 
outsourced by the NITAG or expert group 
Yes 
Evidence assessment required to be 
performed 
Yes 
Contract allows sharing of systematic 
review with other parties 
Yes 
Systematic literature reviews conducted or 
published by others (e.g. Cochrane 
Collaboration) are/can be considered by 
NITAG or expert group/Executive 
Secretariat 
Yes 
Methodological quality of the review 
assessed by NITAG or expert 
group/Executive Secretariat using 
tool/assessment system 
Yes 
Name of tool(s) (e.g. AMSTAR) AMSTAR 
Mathematical modelling (e.g. transmission modelling) 
Recommendation development process 
includes consideration of results from 
mathematical modelling 
Yes 
Developed by Robert Koch Institute 
Outsourced 
Experience with adopting existing models 
from other countries to own setting 
Yes 
Health economic evaluations (e.g. cost-effectiveness studies) 
Recommendation development process 
includes consideration of results from 
health economic evaluations 
Yes 
Contains cost-effectiveness threshold No 
Cost-effectiveness threshold (e.g. per 
QALY) 
Not applicable 
Cost-effectiveness threshold definite 
criterion for/against vaccine introduction 
Not applicable 
Tender system in place  Yes  
National/regional/local In some federal states (for selected vaccines) 
Decision communication 
Rationale for vaccine recommendation 
published 
Yes 
Rationale includes Narrative summary 
Detailed results of systematic reviews including meta-analysis 













GREECE (validated)   As of 30 April 2014 
General facts 
Name of recommending body Εθνική Επιτροπή Εμβολιασμών  
English:  
National Committee on Immunisations 
Self-designation as National Immunisation 
Technical Advisory Group (NITAG) 
Yes 
Contact Prof. Andreas Konstantopoulos, Head of the National Immunisation Committee 
Year established 1991 
Website www.diavgeia.gov.gr 
Website material in English No 
NITAG or /expert group executive 
secretariat/administrative office 
Yes 
NITAG or expert group receives 
(additional) scientific support from: 
National Public Health Institute 
Number of NITAG or expert group 
members 
11 
NITAG or expert group chair is 
elected/appointed by 
Ministry of Health 
Voting-member composition Clinicians, epidemiologists, immunologists, paediatricians, public health experts, 
vaccinology experts 
Voting member(s) from Ministry of Health Yes 
Declaration of conflict of interest No 
Number of meetings per year 3–5 
Meetings open to public No 
Minutes published online No 
NITAG or expert group advises Ministry of Health 
Final decision-maker for vaccine 
introduction in the national programme 
Ministry of Health 
Funding scheme for vaccinations in the 
national immunisation schedule 
Tax-funded 
 
Vaccine recommendation process 
Systematic approach 
NITAG or expert group uses systematic 
approach for the development of national 
vaccine recommendations  
No 
Key elements of the systematic approach Not applicable 
Fixed list of key criteria which need to be 
addressed during  the development 
process  
Not applicable 
List of criteria Not applicable 
Systematic approach published Not applicable 
URL Not applicable 
Systematic literature review 
Recommendation development process 
requires systematic literature review  
Yes 
Systematic literature review is conducted 
by the NITAG or expert group/Executive 
Secretariat itself 
Yes 
Data source(s) Peer-reviewed 
Evidence assessment performed with 
tool/system 
No 
Name of applied risk of bias tool(s) (e.g. 
CASP) or grading system(s) (e.g. GRADE) 
Not applicable 
Systematic literature review is/can be 
outsourced by the NITAG or expert group 
No 
Evidence assessment required to be 
performed 
Not applicable 
Contract allows sharing of systematic 
review with other parties 
Not applicable 
Systematic literature reviews conducted or 
published by others (e.g. Cochrane 
Collaboration) are/can be considered by 















Vaccine recommendation process 
Methodological quality of the review 
assessed by NITAG or expert 
group/Executive Secretariat using 
tool/assessment system 
No 
Name of tool(s) (e.g. AMSTAR) Not applicable 
Mathematical modelling (e.g. transmission modelling) 
Recommendation development process 
includes consideration of results from 
mathematical modelling 
No 
Developed by Not applicable 
Experience with adopting existing models 
from other countries to own setting 
Not applicable 
Health economic evaluations (e.g. cost-effectiveness studies) 
Recommendation development process 
includes consideration of results from 
health economic evaluations 
No 
Contains cost-effectiveness threshold Not applicable 
Cost-effectiveness threshold (e.g. per 
QALY) 
Not applicable 
Cost-effectiveness threshold definite 
criterion for/against vaccine introduction 
Not applicable 
Tender system in place  Yes 
National/regional/local National 
Decision communication 
Rationale for vaccine recommendation 
published 
No 














ICELAND (validated)   As of 30 April 2014 
General facts 
Name of recommending body Sóttvarnaráð  
English:  
National Committee on Communicable Diseases 
Self-designation as National Immunisation 
Technical Advisory Group (NITAG) 
Yes 
Contact Haraldur Briem, State Epidemiologist 
Ólafur Guðlaugsson, NITAG chair 
Year established 1998 
Website No 
Website material in English Not applicable 
NITAG or /expert group executive 
secretariat/administrative office 
Yes 
NITAG or expert group receives 
(additional) scientific support from: 
Icelandic State Epidemiologist 
Number of NITAG or expert group 
members 
7 
NITAG or expert group chair is 
elected/appointed by 
Ministry of Health 
Voting-member composition Clinicians, epidemiologists, public health experts, virologists/microbiologists 
Voting member(s) from Ministry of Health No 
Declaration of conflict of interest No 
Number of meetings per year 3–5 
Meetings open to public No 
Minutes published online No 
NITAG or expert group advises Ministry of Health 
Final decision-maker for vaccine 
introduction in the national programme 
Ministry of Health 
Funding scheme for vaccinations in the 
national immunisation schedule 
Tax-funded 
 
Vaccine recommendation process 
Systematic approach 
NITAG or expert group uses systematic 
approach for the development of national 
vaccine recommendations  
No 
Key elements of the systematic approach Not applicable 
Fixed list of key criteria which need to be 
addressed during  the development 
process  
Not applicable 
List of criteria Not applicable 
Systematic approach published Not applicable 
URL Not applicable 
Systematic literature review 
Recommendation development process 
requires systematic literature review  
No 
Systematic literature review is conducted 
by the NITAG or expert group/Executive 
Secretariat itself 
Yes 
Data source(s) Peer-reviewed 
Evidence assessment performed with 
tool/system 
No 
Name of applied risk of bias tool(s) (e.g. 
CASP) or grading system(s) (e.g. GRADE) 
Not applicable 
Systematic literature review is/can be 
outsourced by the NITAG or expert group 
No 
Evidence assessment required to be 
performed 
Not applicable 
Contract allows sharing of systematic 
review with other parties 
Not applicable 
Systematic literature reviews conducted or 
published by others (e.g. Cochrane 
Collaboration) are/can be considered by 















Vaccine recommendation process 
Methodological quality of the review 
assessed by NITAG or expert 
group/Executive Secretariat using 
tool/assessment system 
No 
Name of tool(s) (e.g. AMSTAR) Not applicable 
Mathematical modelling (e.g. transmission modelling) 
Recommendation development process 
includes consideration of results from 
mathematical modelling 
Yes 
Developed by NITAG 
Experience with adopting existing models 
from other countries to own setting 
Yes 
Health economic evaluations (e.g. cost-effectiveness studies) 
Recommendation development process 
includes consideration of results from 
health economic evaluations 
Yes 
Contains cost-effectiveness threshold No 
Cost-effectiveness threshold (e.g. per 
QALY) 
Not applicable 
Cost-effectiveness threshold definite 
criterion for/against vaccine introduction 
Not applicable 
Tender system in place  Yes 
National/regional/local National 
Decision communication 
Rationale for vaccine recommendation 
published 
No 














IRELAND (validated) As of 30 April 2014 
General facts 
Name of recommending body National Immunisation Advisory Committee (NIAC) 
Self-designation as National Immunisation 
Technical Advisory Group (NITAG) 
Yes 
Contact National Immunisation Advisory Committee 
Year established 1996 
Website No 
Website material in English Not applicable 
NITAG or /expert group executive 
secretariat/administrative office 
Yes 
NITAG or expert group receives 
(additional) scientific support from: 
Health Protection Surveillance Centre, National Centre for Pharmacoeconomics 
Number of NITAG or expert group 
members 
18 
NITAG or expert group chair is 
elected/appointed by 
Royal College of Physicians of Ireland 
Voting-member composition Clinicians, epidemiologists, immunologists, paediatricians, public health experts, 
vaccinology experts, virologists/microbiologists 
Voting member(s) from Ministry of Health Yes 
Declaration of conflict of interest Yes 
Number of meetings per year > 5 
Meetings open to public No 
Minutes published online No 
NITAG or expert group advises Department of Health (=Ministry of Health) 
Final decision-maker for vaccine 
introduction in the national programme 
Department of Health 
Funding scheme for vaccinations in the 
national immunisation schedule 
Tax-funded 
 
Vaccine recommendation process 
Systematic approach 
NITAG or expert group uses systematic 
approach for the development of national 
vaccine recommendations  
Yes 
Key elements of the systematic approach - Quality/safety/efficacy of the vaccine 
- Burden of disease 
- Economic sustainability 
- Integration in the existing schedule 
Fixed list of key criteria which need to be 
addressed during  the development 
process  
Yes 
List of criteria - How common and how serious is the disease? 
- Is there any other way, apart from a vaccine, of protecting people from the 
disease? 
- Is the vaccine safe, does it work, and can the country afford it? 
- Can the vaccine easily be added to the existing vaccine programmes? 
- How will the vaccine be accepted by those for whom it is recommended? 
Systematic approach published No 
URL Not applicable 
Systematic literature review 
Recommendation development process 
requires systematic literature review  
No 
Systematic literature review is conducted 
by the NITAG or expert group/Executive 
Secretariat itself 
Yes 
Data source(s) Peer-reviewed 
Evidence assessment performed with 
tool/system 
Yes 
Name of applied risk of bias tool(s) (e.g. 
CASP) or grading system(s) (e.g. GRADE) 
CASP 
Systematic literature review is/can be 
outsourced by the NITAG or expert group 
No 
Evidence assessment required to be 
performed 
Not applicable 
Contract allows sharing of systematic 














Vaccine recommendation process 
Systematic literature reviews conducted or 
published by others (e.g. Cochrane 
Collaboration) are/can be considered by 
NITAG or expert group/Executive 
Secretariat 
Yes 
Methodological quality of the review 
assessed by NITAG or expert 
group/Executive Secretariat using 
tool/assessment system 
No 
Name of tool(s) (e.g. AMSTAR) Not applicable 
Mathematical modelling (e.g. transmission modelling) 
Recommendation development process 
includes consideration of results from 
mathematical modelling 
Yes 
Developed by National Centre for Pharmacoeconomics 
Experience with adopting existing models 
from other countries to own setting 
Yes 
Health economic evaluations (e.g. cost-effectiveness studies) 
Recommendation development process 
includes consideration of results from 
health economic evaluations 
Yes 
Contains cost-effectiveness threshold Yes 
Cost-effectiveness threshold (e.g. per 
QALY) 
EUR 45 000/QALY 
Cost-effectiveness threshold definite 
criterion for/against vaccine introduction 
Yes 
Tender system in place  Yes 
National/regional/local National 
Decision communication 
Rationale for vaccine recommendation 
published 
No 













ITALY (validated) As of 30 April 2014  
General facts 
Name of recommending body Gruppo Istruttorie Vaccini  
English:  
Group of experts for investigations on vaccines 
Self-designation as National Immunisation 
Technical Advisory Group (NITAG) 
No 
Contact Stefania Iannazzo, MD PHD, Medical Officer, Infectious Diseases Unit – Ministry of 
Health 
Silvia Declich, Chief of the Epidemiology of Infectious Diseases Unit – National 
Centre for Epidemiology/ISS 
Year established 2013 
Website No 
Website material in English Not applicable 
NITAG or expert group Executive 
Secretariat/administrative office 
Not applicable 
NITAG or expert group receives 
(additional) scientific support from: 
Not applicable 
Number of NITAG or expert group 
members 
10 
NITAG or expert group chair is 
elected/appointed by 
Director of National Centre for Epidemiology/ISS 
Voting-member composition No voting takes place 
Member composition: Experts in infectious disease epidemiology, systematic 
reviews, pharmaco-epidemiology  
Voting member(s) from Ministry of Health No/Not applicable 
Declaration of conflict of interest Yes 
Number of meetings per year Not applicable 
Meetings open to public No 
Minutes published online No 
NITAG or expert group advises Ministry of Health 
Final decision-maker for vaccine 
introduction in the national programme 
Ministry of Health and Regional Health Authorities 
Funding scheme for vaccinations in the 
national immunisation schedule 
Tax-funded 
 
Vaccine recommendation process 
Systematic approach 
NITAG or expert group uses systematic 
approach for the development of national 
vaccine recommendations  
Yes 
Key elements of the systematic approach According to the key elements defined in the WHO guidelines (WHO/IVB/05.18: 
http://www.who.int/immunization/documents/WHO_IVB_05.18/en/) 
 Identification of relevant questions 
 Systematic review 
Fixed list of key criteria which need to be 
addressed during  the development 
process  
Yes 
List of criteria According to the criteria defined in the WHO guidelines (WHO/IVB/05.18, see 
above):  
The expert group analyses 
 Disease burden 
 Efficacy, quality and safety 
 Alternative interventions (including other vaccines) 
 Vaccine presentation  
Economic and financial issues are kept in consideration for the final decision of 
inclusion in the national immunisation plan. 
Systematic approach published Yes 
URL http://www.salute.gov.it/imgs/C_17_pubblicazioni_1721_allegato.pdf 
Systematic literature review 
Recommendation development process 
requires systematic literature review  
Yes 
Systematic literature review is conducted 
by NITAG or expert group/Executive 
Secretariat itself 
Yes 
Data source(s) Peer-reviewed 
Unpublished/non-peer reviewed (e.g. regional/national surveillance data and 













Evidence assessment performed with 
tool/system 
No 
Name of applied risk of bias tool(s) (e.g. 
CASP) or grading system(s) (e.g. GRADE) 
Not applicable 
Systematic literature review is/can be 
outsourced by the NITAG or expert group 
No 
Evidence assessment required to be 
performed 
Not applicable 
Contract allows sharing of systematic 
review with other parties 
Not applicable 
Systematic literature reviews conducted or 
published by others (e.g. Cochrane 
Collaboration) are/can be considered by 
NITAG or expert group/Executive 
Secretariat 
Yes 
Methodological quality of the review 
assessed by NITAG or expert 
group/Executive Secretariat using 
tool/assessment system 
No 
Name of tool(s) (e.g. AMSTAR) Not applicable 
Mathematical modelling (e.g. transmission modelling) 
Recommendation development process 
includes consideration of results from 
mathematical modelling 
Yes 
Developed by expert group  
Experience with adopting existing models 
from other countries to own setting 
Yes 
Health economic evaluations (e.g. cost-effectiveness studies) 
Recommendation development process 
includes consideration of results from 
health economic evaluations 
Yes 
Contains cost-effectiveness threshold No 
Cost-effectiveness threshold (e.g. per 
QALY) 
Not applicable 
Cost-effectiveness threshold definite 
criterion for/against vaccine introduction 
Not applicable 
Tender system in place  Yes 
National/regional/local National, regional and local 
Decision communication 
Rationale for vaccine recommendation 
published 
No 













LATVIA (validated)  As of 30 April 2014 
General facts 
Name of recommending body Imunizācijas valsts padome  
English:  
The State Immunisation Advisory Council 
Self-designation as National Immunisation 
Technical Advisory Group (NITAG) 
Yes 
Contact Dr. Jurijs Perevoscikovs, NITAG chair 
Dr. Irina Lucenko, NITAG Secretary 
Year established 2000 
Website http://www.spkc.gov.lv/imunizacijas-valsts-padome/ 
Website material in English No 
NITAG or /expert group executive 
secretariat/administrative office 
No 
NITAG or expert group receives 
(additional) scientific support from: 
Centre for Diseases Prevention and Control of Latvia – infectious diseases 
surveillance, immunisation monitoring and Adverse Events Following Immunisation 
(AEFI) data, secretary functions 
Number of NITAG or expert group 
members 
15 
NITAG or expert group chair is 
elected/appointed by 
Ministry of Health 
Voting-member composition Clinicians, epidemiologists, health economists, immunologists, paediatricians, 
public health experts, vaccinology experts, Ministry of Health, National Regulatory 
Authority on Medicines, NGO, academics  
Voting member(s) from Ministry of Health Yes 
Declaration of conflict of interest No 
Number of meetings per year ≥2 
Meetings open to public Yes 
Minutes published online Yes 
NITAG or expert group advises Ministry of Health 
Final decision-maker for vaccine 
introduction in the national programme 
Ministry of Health, then by the Cabinet of Ministers 
Funding scheme for vaccinations in the 
national immunisation schedule 
Tax-funded 
 
Vaccine recommendation process 
Systematic approach 
NITAG or expert group uses systematic 
approach for the development of national 
vaccine recommendations  
Yes 
Key elements of the systematic approach - Disease burden 
- Severity of disease 
- Vaccine effectiveness 
- Vaccine safety 
- Experience of other countries 
- Financial opportunities 
- Possibility to include new vaccine in immunisation schedule 
- Existence of combined vaccines  
Fixed list of key criteria which need to be 
addressed during  the development 
process  
No 
List of criteria Not applicable 
Systematic approach published No 
URL Not applicable 
Systematic literature review 
Recommendation development process 
requires systematic literature review  
No 
Systematic literature review is conducted 
by the NITAG or expert group/Executive 
Secretariat itself 
No 
Data source(s) Not applicable 
Evidence assessment performed with 
tool/system 
Not applicable 
Name of applied risk of bias tool(s) (e.g. 
CASP) or grading system(s) (e.g. GRADE) 
Not applicable 
Systematic literature review is/can be 
outsourced by the NITAG or expert group 
No 















Vaccine recommendation process 
Contract allows sharing of systematic 
review with other parties 
Not applicable 
Systematic literature reviews conducted or 
published by others (e.g. Cochrane 
Collaboration) are/can be considered by 
NITAG or expert group/Executive 
Secretariat 
Yes 
Methodological quality of the review 
assessed by NITAG or expert 
group/Executive Secretariat using 
tool/assessment system 
No 
Name of tool(s) (e.g. AMSTAR) Not applicable 
Mathematical modelling (e.g. transmission modelling) 
Recommendation development process 
includes consideration of results from 
mathematical modelling 
No 
Developed by Not applicable 
Experience with adopting existing models 
from other countries to own setting 
Not applicable 
Health economic evaluations (e.g. cost-effectiveness studies) 
Recommendation development process 
includes consideration of results from 
health economic evaluations 
No 
Contains cost-effectiveness threshold Not applicable 
Cost-effectiveness threshold (e.g. per 
QALY) 
Not applicable 
Cost-effectiveness threshold definite 
criterion for/against vaccine introduction 
Not applicable 
Tender system in place  Yes 
 National/regional/local National 
Decision communication 
Rationale for vaccine recommendation 
published 
No 
Rationale includes Not applicable 
 












LITHUANIA (validated)  As of 30 April 2014 
General facts 
Name of recommending body Nacionalines imunoprofilaktikos programos koordinavimo taryba  
English:  
Coordinating Council of National Immunisation Programme 
Self-designation as National Immunisation 
Technical Advisory Group (NITAG) 
Yes 
Contact Prof. Daiva Razmuviene, Head of Immunoprophylaxis Division, Centre for 
Communicable diseases and AIDS 
Year established 1999 
Website No 
Website material in English Not applicable 
NITAG or /expert group executive 
secretariat/administrative office 
No 
NITAG or expert group receives 
(additional) scientific support from: 
No 
Number of NITAG or expert group 
members 
11 
NITAG or expert group chair is 
elected/appointed by 
Ministry of Health 
Voting-member composition Clinicians, epidemiologists, immunologists, paediatricians, public health experts, 
vaccinology experts 
Voting member(s) from Ministry of Health Yes 
Declaration of conflict of interest Yes 
Number of meetings per year 3–5 
Meetings open to public No 
Minutes published online No 
NITAG or expert group advises Ministry of Health 
Final decision-maker for vaccine 
introduction in the national programme 
Ministry of Health 
Funding scheme for vaccinations in the 
national immunisation schedule 
Tax-funded 
 
Vaccine recommendation process 
Systematic approach 
NITAG or expert group uses systematic 
approach for the development of national 
vaccine recommendations  
Yes 
Key elements of the systematic approach - Disease burden 
- Severity of disease 
- Vaccine effectiveness 
- Experience of other countries 
- Financial opportunities 
Fixed list of key criteria which need to be 
addressed during  the development 
process  
No 
List of criteria Not applicable 
Systematic approach published No 
URL Not applicable 
Systematic literature review 
Recommendation development process 
requires systematic literature review  
No 
Systematic literature review is conducted 
by the NITAG or expert group/Executive 
Secretariat itself 
No 
Data source(s) Not applicable 
Evidence assessment performed with 
tool/system 
Not applicable 
Name of applied risk of bias tool(s) (e.g. 
CASP) or grading system(s) (e.g. GRADE) 
Not applicable 
Systematic literature review is/can be 
outsourced by the NITAG or expert group 
No 
Evidence assessment required to be 
performed 
Not applicable 
Contract allows sharing of systematic 














Vaccine recommendation process 
Systematic literature reviews conducted or 
published by others (e.g. Cochrane 
Collaboration) are/can be considered by 
NITAG or expert group/Executive 
Secretariat 
Yes 
Methodological quality of the review 
assessed by NITAG or expert 
group/Executive Secretariat using 
tool/assessment system 
No 
Name of tool(s) (e.g. AMSTAR) Not applicable 
Mathematical modelling (e.g. transmission modelling) 
Recommendation development process 
includes consideration of results from 
mathematical modelling 
No 
Developed by Not applicable 
Experience with adopting existing models 
from other countries to own setting 
Not applicable 
Health economic evaluations (e.g. cost-effectiveness studies) 
Recommendation development process 
includes consideration of results from 
health economic evaluations 
No 
Contains cost-effectiveness threshold Not applicable 
Cost-effectiveness threshold (e.g. per 
QALY) 
Not applicable 
Cost-effectiveness threshold definite 
criterion for/against vaccine introduction 
Not applicable 
Tender system in place  Yes 
 National/regional/local National 
Decision communication 
Rationale for vaccine recommendation 
published 
No 













MALTA (validated)   As of 30 April 2014 
General facts 
Name of recommending body Advisory Committee on Immunisation Policy (ACIP) 
Self-designation as National 
Immunisation Technical Advisory 
Group (NITAG) 
Yes 
Contact Dr Charmaine Gauci, Director Health Promotion and Disease Prevention 
Year established 2007 
Website https://ehealth.gov.mt/HealthPortal/others/regulatory_councils/regulatory_councils_list.aspx 
Website material in English Yes 
NITAG or /expert group executive 
secretariat/administrative office 
No 
NITAG or expert group receives 
(additional) scientific support 
from: 
Not applicable 
Number of NITAG or expert group 
members 
8 
NITAG or expert group chair is 
elected/appointed by 
Ministry of Health 
Voting-member composition Clinicians, epidemiologists, paediatricians, public health experts, virologists/microbiologists 
Voting member(s) from Ministry 
of Health 
Yes  
(all NITAG members are employed by the Ministry of Health; the National Public Health 
Institute is a department of the Ministry of Health) 
Declaration of conflict of interest Yes 
Number of meetings per year > 5 
Meetings open to public No 
Minutes published online No 
NITAG or expert group advises Superintendent of Public Health 
Final decision-maker for vaccine 
introduction in the national 
programme 
Ministry of Health (discussed with Ministry of Finance whether funding is available) 
Funding scheme for vaccinations 




Vaccine recommendation process 
Systematic approach 
NITAG or expert group uses systematic 
approach for the development of national 
vaccine recommendations  
Yes 
Key elements of the systematic approach Health Technology Assessment (includes epidemiological data) 
Cost-effectiveness analysis 
Fixed list of key criteria which need to be 
addressed during  the development 
process  
Yes 
List of criteria • Cost-effectiveness 
• Impact of decrease in disease burden 
• Priority 
Systematic approach published No 
URL Not applicable 
Systematic literature review 
Recommendation development process 
requires systematic literature review  
No 
Systematic literature review is conducted 
by the NITAG or expert group/Executive 
Secretariat itself 
No 
Data source(s) Not applicable 
Evidence assessment performed with 
tool/system 
Not applicable 
Name of applied risk of bias tool(s) (e.g. 
CASP) or grading system(s) (e.g. GRADE) 
Not applicable 
Systematic literature review is/can be 
outsourced by the NITAG or expert group 
No 
Evidence assessment required to be 
performed 
Not applicable 
Contract allows sharing of systematic 














Vaccine recommendation process 
Systematic literature reviews conducted or 
published by others (e.g. Cochrane 
Collaboration) are/can be considered by 
NITAG or expert group/Executive 
Secretariat 
Yes 
Methodological quality of the review 
assessed by NITAG or expert 
group/Executive Secretariat using 
tool/assessment system 
No 
Name of tool(s) (e.g. AMSTAR) Not applicable 
Mathematical modelling (e.g. transmission modelling) 
Recommendation development process 
includes consideration of results from 
mathematical modelling 
Yes 
Developed by Existing literature 
Experience with adopting existing models 
from other countries to own setting 
Not applicable 
Health economic evaluations (e.g. cost-effectiveness studies) 
Recommendation development process 
includes consideration of results from 
health economic evaluations 
Yes 
Contains cost-effectiveness threshold No 
Cost-effectiveness threshold (e.g. per 
QALY) 
Not applicable 
Cost-effectiveness threshold definite 
criterion for/against vaccine introduction 
Not applicable 
Tender system in place  Yes  
National/regional/local National 
Decision communication 
Rationale for vaccine recommendation 
published 
No 














NETHERLANDS (validated)  As of 30 April 2014 
General facts 
Name of recommending body Gezondheidsraad 
English:  
Health Council in the Netherlands – Committee on Vaccinations  
Self-designation as National Immunisation 
Technical Advisory Group (NITAG) 
Yes 
Contact Leo van Rossum PhD, NITAG Executive Secretariat 
Hans Houweling MD PhD, NITAG Executive Secretariat 
Year established 1902 
Website www.healthcouncil.nl 
Website material in English Yes 
NITAG or /expert group executive 
secretariat/administrative office 
Yes 
NITAG or expert group receives 
(additional) scientific support from: 
National Institute of Public Health (RIVM) 
Number of NITAG or expert group 
members 
About 20 
NITAG or expert group chair is 
elected/appointed by 
The President of the Health Council 
Voting-member composition Clinicians, epidemiologists, immunologists, paediatricians, public health experts, 
vaccinology experts, virologists/microbiologists, ethicist 
Voting member(s) from Ministry of Health No 
Declaration of conflict of interest Yes 
Number of meetings per year > 5 
Meetings open to public No 
Minutes published online No 
NITAG or expert group advises Minister of Health 
Final decision-maker for vaccine 
introduction in the national programme 
Minister of Health 
Funding scheme for vaccinations in the 
national immunisation schedule 
Tax-funded 
 
Vaccine recommendation process 
Systematic approach 
NITAG or expert group uses systematic 
approach for the development of national 
vaccine recommendations  
Yes 
Key elements of the systematic approach • Seriousness and extent of disease burden 
• Effectiveness and safety of vaccination 
• Acceptability of vaccination 
• Efficiency of vaccination 
• Priority of vaccination 
Fixed list of key criteria which need to be 
addressed during  the development 
process  
Yes 
List of criteria • Seriousness and extent of disease burden 
• Effectiveness and safety of vaccination 
• Acceptability of vaccination 
• Efficiency of vaccination 
• Priority of vaccination 
Systematic approach published Yes 
URL • http://gr.nl/sites/default/files/200702E_0.pdf  
• Houweling H, Verweij M, Ruitenberg EJ. Criteria for inclusion of vaccinations in 
public programmes. Vaccine 2010; 28: 2924-2931. 
Systematic literature review 
Recommendation development process 
requires systematic literature review  
Yes 
Systematic literature review is conducted 
by the NITAG or expert group/Executive 
Secretariat itself 
Yes 
Data source(s) Peer-reviewed 
Evidence assessment performed with 
tool/system 
No 
Name of applied risk of bias tool(s) (e.g. 
CASP) or grading system(s) (e.g. GRADE) 
Not applicable 
Systematic literature review is/can be 
outsourced by the NITAG or expert group 
Yes 















Vaccine recommendation process 
Contract allows sharing of systematic 
review with other parties 
Yes 
Systematic literature reviews conducted or 
published by others (e.g. Cochrane 
Collaboration) are/can be considered by 
NITAG or expert group/Executive 
Secretariat 
Yes 
Methodological quality of the review 
assessed by NITAG or expert 
group/Executive Secretariat using 
tool/assessment system 
No 
Name of tool(s) (e.g. AMSTAR) Not applicable 
Mathematical modelling (e.g. transmission modelling) 
Recommendation development process 
includes consideration of results from 
mathematical modelling 
Yes 
Developed by NITAG 
Outsourced 
Experience with adopting existing models 
from other countries to own setting 
Yes 
Health economic evaluations (e.g. cost-effectiveness studies) 
Recommendation development process 
includes consideration of results from 
health economic evaluations 
Yes 
Contains cost-effectiveness threshold No formal threshold 
Cost-effectiveness threshold (e.g. per 
QALY) 
Informally EUR 20 000/QALY 
Cost-effectiveness threshold definite 
criterion for/against vaccine introduction 
No 
Tender system in place  Yes 
 National/regional/local National 
Decision communication 
Rationale for vaccine recommendation 
published 
Yes 
Rationale includes Narrative summary 
Detailed results of systematic reviews including meta-analysis 













NORWAY (validated)   As of 30 April 2014 
General facts 
Name of recommending body Names differ as the recommending bodies are ad hoc, topic-related expert 
group(s)  
Self-designation as National Immunisation 
Technical Advisory Group (NITAG) 
No 
Contact Britt Wolden, Director, Department of Vaccines, Norwegian Institute of Public 
Health 
Year established First expert group active in 1991  
Website No 
Website material in English Not applicable 
NITAG or /expert group executive 
secretariat/administrative office 
Yes 
NITAG or expert group receives 
(additional) scientific support from: 
Not applicable  
Number of NITAG or expert group 
members 
8–12 (including Norwegian Institute of Public Health experts) 
NITAG or expert group chair is 
elected/appointed by 
Usually appointed by Norwegian Institute of Public Health 
Voting-member composition No voting takes place 
Member composition: Clinicians, epidemiologists, immunologists, paediatricians, 
public health experts, vaccinology experts, virologists/microbiologists, other 
medical specialties when relevant (gynaecologists, pathologists), public health 
nurses 
Voting member(s) from Ministry of Health No 
Declaration of conflict of interest Yes 
Number of meetings per year No fixed number of meetings  
Meetings open to public No 
Minutes published online No 
NITAG or expert group advises Norwegian Institute of Public Health (that advises the Ministry of Health) 
Final decision-maker for vaccine 
introduction in the national programme 
Ministry of Health (Parliament in case of large economic impact) 
Funding scheme for vaccinations in the 
national immunisation schedule 
Tax-funded 
 
Vaccine recommendation process 
Systematic approach 
NITAG or expert group uses systematic 
approach for the development of national 
vaccine recommendations  
Yes 
Key elements of the systematic approach • Literature search 
• Country-specific epidemiology and burden of disease 
• Feasibility/possibility for implementation in the vaccination programme 
• Attitudes in the population 
• Cost-effectiveness analysis 
Fixed list of key criteria which need to be 
addressed during  the development 
process  
Yes 
List of criteria • Literature search 
• Country-specific epidemiology and burden of disease 
• Feasibility/possibility for implementation in the vaccination programme 
• Attitudes in the population 
• Cost-effectiveness analysis 
Systematic approach published No 
URL Not applicable 
Systematic literature review 
Recommendation development process 
requires systematic literature review  
Yes 
Systematic literature review is conducted 
by the NITAG or expert group/Executive 
Secretariat itself 
Yes 
Data source(s) Peer-reviewed 
Evidence assessment performed with 
tool/system 
No 
Name of applied risk of bias tool(s) (e.g. 
CASP) or grading system(s) (e.g. GRADE) 
Not applicable 
Systematic literature review is/can be 
outsourced by the NITAG or expert group 
Yes 















Vaccine recommendation process 
Contract allows sharing of systematic 
review with other parties 
Yes 
Systematic literature reviews conducted or 
published by others (e.g. Cochrane 
Collaboration) are/can be considered by 
NITAG or expert group/Executive 
Secretariat 
Yes 
Methodological quality of the review 
assessed by NITAG or expert 
group/Executive Secretariat using 
tool/assessment system 
No 
Name of tool(s) (e.g. AMSTAR) Not applicable 
Mathematical modelling (e.g. transmission modelling) 
Recommendation development process 
includes consideration of results from 
mathematical modelling 
Yes 
Developed by Norwegian Public Health Institute 
Outsourced 
Experience with adopting existing models 
from other countries to own setting 
Yes  
Health economic evaluations (e.g. cost-effectiveness studies) 
Recommendation development process 
includes consideration of results from 
health economic evaluations 
Yes 
Contains cost-effectiveness threshold Yes 
Cost-effectiveness threshold (e.g. per 
QALY) 
No fixed number 
Cost-effectiveness threshold definite 
criterion for/against vaccine introduction 
No 
Tender system in place  Yes  
National/regional/local National 
Decision communication 
Rationale for vaccine recommendation 
published 
Yes 
Rationale includes Narrative summary 













POLAND (validated)   As of 30 April 2014 
General facts 
Name of recommending body (1) Rada Sanitarno-Epidemiologiczna i  
(2) Pediatryczny Zespół Ekspertów do Spraw Programu Szczepień Ochronnych  
English:  
(1) Sanitary- Epidemiology Advisory Board   
(2) Pediatric Group of Experts on Immunisation Program 
Self-designation as National Immunisation 
Technical Advisory Group (NITAG) 
Yes 
 
Contact 1) Chief Sanitary Inspectorate and  
2) Department of Mother and Child 
Year established 2003 
Website No 
Website material in English Not applicable  
NITAG or /expert group executive 
secretariat/administrative office 
No 
NITAG or expert group receives 
(additional) scientific support from: 
Experts from The National Institute of Public Health – National Institute of Hygiene 
(NIPH-NIH) and Polish Medical Societies (e.g. Pediatrics, Vaccinology, 
Epidemiology), institutes and universities 




NITAG or expert group chair is 
elected/appointed by 
(1) Ministry of Health 
(2) Ministry of Health at request of Sanitary Inspector 
Voting-member composition Clinicians, epidemiologists, immunologists, paediatricians, public health experts, 
vaccinology experts, virologists/microbiologists 
Voting member(s) from Ministry of Health No 
Declaration of conflict of interest No 
Number of meetings per year 3–5 (additional meetings if necessary) 
Meetings open to public No 
Minutes published online No 
NITAG or expert group advises Ministry of Health 
Final decision-maker for vaccine 
introduction in the national programme 
Ministry of Health 
Funding scheme for vaccinations in the 
national immunisation schedule 
Tax-funded (for mandatory vaccines, recommended vaccines are paid by individual) 
 
Vaccine recommendation process 
Systematic approach 
NITAG or expert group uses systematic 
approach for the development of national 
vaccine recommendations  
Yes 
Key elements of the systematic approach • Burden of disease 
• Efficacy 
• Effectiveness 
• Safety of the vaccine 
• Pharmacoeconomics analysis 
Fixed list of key criteria which need to be 
addressed during  the development 
process  
No 
List of criteria Not applicable 
 
Systematic approach published No 
URL Not applicable 
Systematic literature review 
Recommendation development process 
requires systematic literature review  
Yes 
Systematic literature review is conducted 
by the NITAG or expert group/Executive 
Secretariat itself 
No 
Data source(s) Not applicable 
Evidence assessment performed with 
tool/system 
Not applicable  
Name of applied risk of bias tool(s) (e.g. 
CASP) or grading system(s) (e.g. GRADE) 
Not applicable 
Systematic literature review is/can be 
outsourced by the NITAG or expert group 
No  















Vaccine recommendation process 
Contract allows sharing of systematic 
review with other parties 
Not applicable 
 
Systematic literature reviews conducted or 
published by others (e.g. Cochrane 
Collaboration) are/can be considered by 
NITAG or expert group/Executive 
Secretariat 
Yes 
Methodological quality of the review 
assessed by NITAG or expert 
group/Executive Secretariat using 
tool/assessment system 
No 
Name of tool(s) (e.g. AMSTAR) Not applicable 
Mathematical modelling (e.g. transmission modelling) 
Recommendation development process 
includes consideration of results from 
mathematical modelling 
Yes 
Developed by Outsourced 
Experience with adopting existing models 
from other countries to own setting 
Not applicable 
Health economic evaluations (e.g. cost-effectiveness studies) 
Recommendation development process 
includes consideration of results from 
health economic evaluations 
Yes 
Contains cost-effectiveness threshold No 
Cost-effectiveness threshold (e.g. per 
QALY) 
Not applicable 
Cost-effectiveness threshold definite 
criterion for/against vaccine introduction 
Not applicable 
Tender system in place  Yes 
National/regional/local National 
Decision communication 
Rationale for vaccine recommendation 
published 
No 













PORTUGAL (validated)  As of 30 April 2014 
General facts 
Name of recommending body Comissão Técnica de Vacinação  
English:  
National Vaccination Committee 
Self-designation as National Immunisation 
Technical Advisory Group (NITAG) 
Yes 
Contact Dr. Graça Freitas, NITAG 
Year established 1998 
Website No 
Website material in English Not applicable 
NITAG or /expert group executive 
secretariat/administrative office 
Yes 
NITAG or expert group receives 
(additional) scientific support from: 
Mainly from the Directorate-General of Health (DGS) but also other experts, 
depending of the subjects 
Number of NITAG or expert group 
members 
19 
NITAG or expert group chair is 
elected/appointed by 
Director-General of Health, representing the Ministry of Health 
Voting-member composition Experts in Public health, pediatrics, epidemiology, infectiology, family practice, 
modeling, immunology, nursing, pharmacy, biology  
Voting member(s) from Ministry of Health Yes 
Declaration of conflict of interest Yes 
Number of meetings per year ≥ 3 
Meetings open to public No 
Minutes published online No 
NITAG or expert group advises Director-General of Health (advising the Ministry of Health) 
Final decision-maker for vaccine 
introduction in the national programme 
Ministry of Health 
Funding scheme Tax-funded 
 
Vaccine recommendation process 
Systematic approach 
NITAG or expert group uses systematic 
approach for the development of national 
vaccine recommendations  
Yes 
Key elements of the systematic approach 1. Evaluation of available vaccines  
(quality, safety, efficacy/effectiveness, duration of immunity, herd immunity, 
impact on pathogen and on disease epidemiology, compatibility with the NIP 
vaccines, applicability and acceptability) 
2. Disease burden  
(incidence, prevalence, severity, fatality ratio, occurrence of the microorganism, 
others) 
3. Cost-effectiveness studies 
Fixed list of key criteria which need to be 
addressed during  the development 
process  
Yes 
List of criteria 1. Evaluation of available vaccines  
(quality, safety, efficacy/effectiveness, duration of immunity, herd immunity, 
impact on pathogen and on disease epidemiology, compatibility with the NIP 
vaccines, applicability and acceptability) 
2. Disease burden  
(incidence, prevalence, severity, fatality ratio, occurrence of the microorganism, 
others) 
3. Cost-effectiveness studies 
Systematic approach published Yes 
URL http://dre.pt/pdfgratis2s/2013/04/2S078A0000S00.pdf 
Systematic literature review 
Recommendation development process 
requires systematic literature review  
Yes 
Systematic literature review is conducted 
by the NITAG or expert group/Executive 
Secretariat itself 
Yes 
Data source(s) Peer-reviewed 
Unpublished/non-peer reviewed 
Evidence assessment performed with 
tool/system 
No 
Name of applied risk of bias tool(s) (e.g. 














Vaccine recommendation process 
Systematic literature review is/can be 
outsourced by the NITAG or expert group 
Yes 
Evidence assessment required to be 
performed 
No 
Contract allows sharing of systematic 
review with other parties 
Yes 
Systematic literature reviews conducted or 
published by others (e.g. Cochrane 
Collaboration) are/can be considered by 
NITAG or expert group/Executive 
Secretariat 
Yes 
Methodological quality of the review 
assessed by NITAG or expert 
group/Executive Secretariat using 
tool/assessment system 
No 
Name of tool(s) (e.g. AMSTAR) Not applicable 
Mathematical modelling (e.g. transmission modelling) 
Recommendation development process 
includes consideration of results from 
mathematical modelling 
Yes 
Developed by NITAG 
Outsourced 
Experience with adopting existing models 
from other countries to own setting 
Yes 
Health economic evaluations (e.g. cost-effectiveness studies) 
Recommendation development process 
includes consideration of results from 
health economic evaluations 
Yes 
Contains cost-effectiveness threshold No 
Cost-effectiveness threshold (e.g. per 
QALY) 
Not applicable 
Cost-effectiveness threshold definite 
criterion for/against vaccine introduction 
Not applicable 
Tender system in place  No 
National/regional/local Not applicable 
Decision communication 
Rationale for vaccine recommendation 
published 
Yes 
Rationale includes Narrative summary 














ROMANIA (validated)   As of 30 April 2014 
General facts 
Name of recommending body Comitetul National de Vaccinologie  
English:  
National Commitee of Vaccinology 
Self-designation as National Immunisation 
Technical Advisory Group (NITAG) 
Yes 
Contact National Centre for Communicable Diseases Surveillance and Control, NITAG 
Executive Secretariat 
Year established 2008 
Website No 
Website material in English Not applicable 
NITAG or /expert group executive 
secretariat/administrative office 
Yes 
NITAG or expert group receives 
(additional) scientific support from: 
Various experts 
Number of NITAG or expert group 
members 
15 
NITAG or expert group chair is 
elected/appointed by 
NITAG members 
Voting-member composition Clinicians, epidemiologists, immunologists, paediatricians, public health experts, 
vaccinology experts, virologists/microbiologists 
Voting member(s) from Ministry of Health No 
Declaration of conflict of interest Yes 
Number of meetings per year 3–5 
Meetings open to public No 
Minutes published online No 
NITAG or expert group advises Ministry of Health 
Final decision-maker for vaccine 
introduction in the national programme 
Ministry of Health 
Funding scheme for vaccinations in the 
national immunisation schedule 
Tax-funded 
 
Vaccine recommendation process 
Systematic approach 
NITAG or expert group uses systematic 
approach for the development of national 
vaccine recommendations  
Yes 
Key elements of the systematic approach Epidemiological data/disease burden 
Fixed list of key criteria which need to be 
addressed during  the development 
process  
Yes 
List of criteria • Assessment of epidemiological context 
• Age group most exposed 
• Recommended vaccination schemes 
• Implementation/logistical issues 
Systematic approach published No 
URL Not applicable 
Systematic literature review 
Recommendation development process 
requires systematic literature review  
Yes 
Systematic literature review is conducted 
by the NITAG or expert group/Executive 
Secretariat itself 
Yes 
Data source(s) Peer-reviewed 
Evidence assessment performed with 
tool/system 
No 
Name of applied risk of bias tool(s) (e.g. 
CASP) or grading system(s) (e.g. GRADE) 
Not applicable 
Systematic literature review is/can be 
outsourced by the NITAG or expert group 
No 
Evidence assessment required to be 
performed 
Not applicable 
Contract allows sharing of systematic 














Vaccine recommendation process 
Systematic literature reviews conducted or 
published by others (e.g. Cochrane 
Collaboration) are/can be considered by 
NITAG or expert group/Executive 
Secretariat 
Yes 
Methodological quality of the review 
assessed by NITAG or expert 
group/Executive Secretariat using 
tool/assessment system 
No 
Name of tool(s) (e.g. AMSTAR) Not applicable 
Mathematical modelling (e.g. transmission modelling) 
Recommendation development process 
includes consideration of results from 
mathematical modelling 
No 
Developed by Not applicable 
Experience with adopting existing models 
from other countries to own setting 
Not applicable 
Health economic evaluations (e.g. cost-effectiveness studies) 
Recommendation development process 
includes consideration of results from 
health economic evaluations 
No 
Contains cost-effectiveness threshold Not applicable 
Cost-effectiveness threshold (e.g. per 
QALY) 
Not applicable 
Cost-effectiveness threshold definite 
criterion for/against vaccine introduction 
Not applicable 
Tender system in place  Yes 
National/regional/local National 
Decision communication 
Rationale for vaccine recommendation 
published 
No 













SLOVAKIA (validated)  As of 30 April 2014 
General facts 
Name of recommending body Pracovná skupina pre imunizáciu (PSPI)  
English name:  
Working Group for Immunisation (WGFI) 
Self-designation as National Immunisation 
Technical Advisory Group (NITAG) 
Yes 
Contact RN Dr Jan Mikas, NITAG Chair 
Year established 2006 
Website No 
Website material in English Not applicable 
NITAG or /expert group executive 
secretariat/administrative office 
No 
NITAG or expert group receives 
(additional) scientific support from: 
No 
Number of NITAG or expert group 
members 
9 
NITAG or expert group chair is 
elected/appointed by 
Ministry of Health 
Voting-member composition Clinicians, epidemiologists, paediatricians, public health experts, vaccinology 
experts, virologists/microbiologists, pharmaceutists, infectologists, general 
practitioners 
Voting member(s) from Ministry of Health Yes 
Declaration of conflict of interest Yes 
Number of meetings per year 3–5 
Meetings open to public No 
Minutes published online No 
NITAG or expert group advises Chief Hygienist  
Final decision-maker for vaccine 
introduction in the national programme 
Ministry of Health 
Funding scheme for vaccinations in the 
national immunisation schedule 
Social insurance 
 
Vaccine recommendation process 
Systematic approach 
NITAG or expert group uses systematic 
approach for the development of national 
vaccine recommendations  
Yes 
Key elements of the systematic approach • Epidemiological situation in the country 
• WHO recommendations 
Fixed list of key criteria which need to be 
addressed during  the development 
process  
No 
List of criteria Not applicable 
Systematic approach published No 
URL Not applicable 
Systematic literature review 
Recommendation development process 
requires systematic literature review  
Yes 
Systematic literature review is conducted 
by the NITAG or expert group/Executive 
Secretariat itself 
Yes 
Data source(s) Peer-reviewed 
Unpublished/non-peer reviewed evidence 
Evidence assessment performed with 
tool/system 
No  
Name of applied risk of bias tool(s) (e.g. 
CASP) or grading system(s) (e.g. GRADE) 
Not applicable 
Systematic literature review is/can be 
outsourced by the NITAG or expert group 
No 
Evidence assessment required to be 
performed 
Not applicable 
Contract allows sharing of systematic 
review with other parties 
Not applicable 
Systematic literature reviews conducted or 
published by others (e.g. Cochrane 
Collaboration) are/can be considered by 















Vaccine recommendation process 
Methodological quality of the review 
assessed by NITAG or expert 
group/Executive Secretariat using 
tool/assessment system 
No 
Name of tool(s) (e.g. AMSTAR) Not applicable 
Mathematical modelling (e.g. transmission modelling) 
Recommendation development process 
includes consideration of results from 
mathematical modelling 
Yes 
Developed by Outsourced 
Experience with adopting existing models 
from other countries to own setting 
Not applicable 
Health economic evaluations (e.g. cost-effectiveness studies) 
Recommendation development process 
includes consideration of results from 
health economic evaluations 
Yes 
Contains cost-effectiveness threshold No 
Cost-effectiveness threshold (e.g. per 
QALY) 
Not applicable 
Cost-effectiveness threshold definite 
criterion for/against vaccine introduction 
Not applicable 
Tender system in place  No 
National/regional/local Not applicable 
Decision communication 
Rationale for vaccine recommendation 
published 
No 














SLOVENIA (validated)   As of 30 April 2014 
General facts 
Name of recommending body Posvetovalna skupina za cepljenje (PSC)   
English:  
Advisory Group on Immunisation (AGI) 
Self-designation as National Immunisation 
Technical Advisory Group (NITAG) 
Yes 
Contact Marta Grgic Vitek, NIPH, Centre for Communicable Diseases 
Year established 2011 
Website No 
Website material in English Not applicable 
NITAG or /expert group executive 
secretariat/administrative office 
Yes 
NITAG or expert group receives 
(additional) scientific support from: 
National Institute of Public Health 
Number of NITAG or expert group 
members 
9 
NITAG or expert group chair is 
elected/appointed by 
NITAG members 
Voting-member composition Infectious disease specialists, immunologist, paediatricians, pulmonologist, 
allergologist, school doctor, medicinal regulatory scientist 
Voting member(s) from Ministry of Health No 
Declaration of conflict of interest Yes 
Number of meetings per year 3–5 
Meetings open to public Yes 
Minutes published online Yes 
NITAG or expert group advises National Institute of Public Health 
Final decision-maker for vaccine 
introduction in the national programme 
Ministry of Health 
Funding scheme for vaccinations in the 
national immunisation schedule 
Social insurance 
 
Vaccine recommendation process 
Systematic approach 
NITAG or expert group uses systematic 
approach for the development of national 
vaccine recommendations  
No 
Key elements of the systematic approach Not applicable 
Fixed list of key criteria which need to be 
addressed during  the development 
process  
Not applicable 
List of criteria Not applicable 
Systematic approach published Not applicable 
URL Not applicable 
Systematic literature review 
Recommendation development process 
requires systematic literature review  
Yes 
Systematic literature review is conducted 
by the NITAG or expert group/Executive 
Secretariat itself 
No 
Data source(s) Not applicable 
Evidence assessment performed with 
tool/system 
Not applicable 
Name of applied risk of bias tool(s) (e.g. 
CASP) or grading system(s) (e.g. GRADE) 
Not applicable 
Systematic literature review is/can be 
outsourced by the NITAG or expert group 
No 
Evidence assessment required to be 
performed 
Not applicable 
Contract allows sharing of systematic 
review with other parties 
Not applicable 
Systematic literature reviews conducted or 
published by others (e.g. Cochrane 
Collaboration) are/can be considered by 















Vaccine recommendation process 
Methodological quality of the review 
assessed by NITAG or expert 
group/Executive Secretariat using 
tool/assessment system 
No 
Name of tool(s) (e.g. AMSTAR) Not applicable 
Mathematical modelling (e.g. transmission modelling) 
Recommendation development process 
includes consideration of results from 
mathematical modelling 
No 
Developed by Not applicable 
Experience with adopting existing models 
from other countries to own setting 
Not applicable 
Health economic evaluations (e.g. cost-effectiveness studies) 
Recommendation development process 
includes consideration of results from 
health economic evaluations 
Yes 
Contains cost-effectiveness threshold Yes 
Cost-effectiveness threshold (e.g. per 
QALY) 
EUR 30 000/QALY 
Cost-effectiveness threshold definite 
criterion for/against vaccine introduction 
No 
Tender system in place  Yes  
National/regional/local National 
Decision communication 
Rationale for vaccine recommendation 
published 
No 














SPAIN (validated)  As of 30 April 2014 
General facts 
Name of recommending body Ponencia de Programa y Registro de Vacunaciones 
English:  
Immunisation Advisory Committee (IAC) 
Self-designation as National Immunisation 
Technical Advisory Group (NITAG) 
Yes 
Contact Subdirection of Health Promotion and Epidemiology 
Year established 1991 
Website No 
Website material in English Not applicable 
NITAG or /expert group executive 
secretariat/administrative office 
Yes 
NITAG or expert group receives 
(additional) scientific support from: 
Health Institute Carlos III (National Center for Epidemiology and National Center 
for Microbiology), Spanish Medicines Agency 
Number of NITAG or expert group 
members 
19+4 
NITAG or expert group chair is 
elected/appointed by 
Ministry of Health 
Voting-member composition Epidemiologists, paediatricians, public health experts, vaccinology experts, 
virologists/microbiologists 
Voting member(s) from Ministry of Health Yes 
Declaration of conflict of interest No 
Number of meetings per year >2 
Meetings open to public No 
Minutes published online No 
NITAG or expert group advises Commission of Public Health (advising the Interterritorial Council of the National 
Health System) 
Final decision-maker for vaccine 
introduction in the national programme 
Interterritorial Council of the National Health System  
(consists of the national Minster of Health and the regional Ministers of Health) 
Funding scheme for vaccinations in the 
national immunisation schedule 
Tax-funded 
 
Vaccine recommendation process 
Systematic approach 
NITAG or expert group uses systematic 
approach for the development of national 
vaccine recommendations  
Yes 
Key elements of the systematic approach Three consecutive steps: 
(Step 2 is evaluated after criteria of step 1 are considered important from a public 
health perspective, and step 3 after a positive assessment of step 2) 
1. Burden of disease, effectiveness and safety of the vaccine 
2. Impact of modifications in the immunisation programme and ethical aspects 
3. Economic evaluation 
Fixed list of key criteria which need to be 
addressed during  the development 
process  
Yes 
List of criteria 1. Burden of disease 
2. Effectiveness and safety of the vaccine 
3. Impact of modifications in the immunisation programme 
4. Ethical aspects 
5. Economic evaluation 
Systematic approach published Yes 
URL http://www.msssi.gob.es/ciudadanos/proteccionSalud/vacunaciones/docs/Criterios_
ProgramaVacunas.pdf 
Systematic literature review 
Recommendation development process 
requires systematic literature review  
No 
Systematic literature review is conducted 
by the NITAG or expert group/Executive 
Secretariat itself 
Yes (in most cases) 
Data source(s) Peer-reviewed  
Published documents from recognised institutions (ECDC, WHO, and other NITAGs) 
Evidence assessment performed with 
tool/system 
No  
Name of applied risk of bias tool(s) (e.g. 
CASP) or grading system(s) (e.g. GRADE) 
Not applicable 
Systematic literature review is/can be 
outsourced by the NITAG or expert group 













Vaccine recommendation process 
Evidence assessment required to be 
performed 
Yes 
Contract allows sharing of systematic 
review with other parties 
No 
Systematic literature reviews conducted or 
published by others (e.g. Cochrane 
Collaboration) are/can be considered by 
NITAG or expert group/Executive 
Secretariat 
Yes  
Methodological quality of the review 
assessed by NITAG or expert 
group/Executive Secretariat using 
tool/assessment system 
No 
Name of tool(s) (e.g. AMSTAR) Not applicable 
Mathematical modelling (e.g. transmission modelling) 
Recommendation development process 
includes consideration of results from 
mathematical modelling 
Not specifically  
Developed by Not applicable 
Experience with adopting existing models 
from other countries to own setting 
Not applicable 
Health economic evaluations (e.g. cost-effectiveness studies) 
Recommendation development process 
includes consideration of results from 
health economic evaluations 
Yes 
Contains cost-effectiveness threshold No 
Cost-effectiveness threshold (e.g. per 
QALY) 
Not applicable 
Cost-effectiveness threshold definite 
criterion for/against vaccine introduction 
Not applicable 
Tender system in place  No 
National/regional/local Not applicable 
Decision communication 
Rationale for vaccine recommendation 
published 
Yes 
Rationale includes Entire rationale  
Including: 
Narrative summary 













SWEDEN (validated)  As of 30 April 2014 
General facts 
Name of recommending body Expertgrupp and Sakkunniggrupp (assessment of scientific and organisational 
aspects, established for each topic/vaccination) 
Socialstyrelsen (makes recommendation based on scientific assessment)  
English:  
Expert group and assessment group (scientific basis) 
National Board of Health and Welfare (recommendation)  
Self-designation as National Immunisation 
Technical Advisory Group (NITAG) 
No 
Contact Tina Chavoshi, programme officer 
Year established 2014 
Website No 
Website material in English Not applicable 
NITAG or /expert group executive 
secretariat/administrative office 
The scientific groups are supported by the National Board of Health and Welfare 
NITAG or expert group receives 
(additional) scientific support from: 
Expert advice from Swedish Public Health Agency, Medical Products Agency, 
consultants for cost-effectiveness analysis 
Number of NITAG or expert group 
members 
expert group: 4 
Assessment group: 5–10 
(The number of members might differ depending on the topic/vaccination being 
assessed) 
NITAG or expert group chair is 
elected/appointed by 
Expert group and assessment group: No official chair 
Voting-member composition Expert groups include:  
Clinicians, epidemiologists, health economists, immunologists, paediatricians, 
vaccinology experts, virologists/microbiologists, other medical specialties when 
relevant  
Voting member(s) from Ministry of Health Expert group and assessment group: No 
 
Declaration of conflict of interest Expert group and assessment group: Yes 
Number of meetings per year Expert group and assessment group: need of meetings depends on 
topic/vaccination addressed  
Meetings open to public Expert group and assessment group: No 
Minutes published online Expert group and assessment group: No 
NITAG or expert group advises The expert and assessment groups produce the scientific basis/analysis for a 
recommendation. Based on their assessment reports, the National Board of Health 
and Welfare gives a recommendation to the government. 
Final decision-maker for vaccine 
introduction in the national programme 
Government 
Funding scheme for vaccinations in the 
national immunisation schedule 
Tax-funded 
 
Vaccine recommendation process 
Systematic approach 
NITAG or expert group uses systematic 
approach for the development of national 
vaccine recommendations  
Yes 
Key elements of the systematic approach Two prerequisites that have to be fulfilled: 
• A vaccine should be available that can be given without prior diagnosis of the 
disease 
• The vaccine should induce more than short-time immunity against the disease 
 
If the two prerequisites are met the vaccination should be encompassed by the 
National Immunisation Program if the vaccination is expected to:  
• effectively prevent the spread of the disease within the population 
• if it is cost effective  
• if it is sustainable as regards ethical and humanitarian standpoints. 
 
The framework consists of the assessment of three criteria and 13 aspects 
regulated by law (see List of criteria). 
Fixed list of key criteria which need to be 
addressed during  the development 
process  













Vaccine recommendation process 
List of criteria Criteria: 
1. Does it effectively prevent the spread of the disease within the population? 
2. Is it cost-effective? 
3. Is it sustainable from ethical and humanitarian standpoints?  
 
Aspects: 
1. Disease burden in society, health care and for the individual 
2. Expected impact of the vaccination regarding disease epidemiology  
3. Number of doses needed to reach the desired effect 
4. Groups that should be offered vaccination 
5. Safety of the vaccine 
6. Expected outcome/effect of the vaccination on the operation of the counties, 
municipalities and private caregivers  
7. Suitability of the vaccine to combine with vaccinations already part of the 
National Immunisation Program 
8. Public acceptance of the vaccination and its influence on attitudes towards 
vaccinations in general 
9. Other measures or treatments that can be given as an alternative to a national 
immunisation programme 
10. Socioeconomic assessment of the cost-effectiveness of the vaccination and an 
assessment of the costs and incomes to the states, counties, municipalities 
11. Possibilities for follow-up regarding the effect of the vaccination in regard to 
the 10 above mentioned aspects as well as the costs for follow-up/surveillance 
12. Need for information campaigns towards the public and the caregivers and the 
costs thereof 
13. Medical ethical and humanitarian considerations 
Systematic approach published Yes 
URL http://www.socialstyrelsen.se/publikationer2013/2013-11-9 
Systematic literature review 
Recommendation development process 
requires systematic literature review  
Yes, if possible 
Systematic literature review is conducted 
by the NITAG or expert group/Executive 
Secretariat itself 
Yes, if possible 
Data source(s) Peer-reviewed 
Unpublished/non-peer reviewed 
Evidence assessment performed with 
tool/system 
Yes, when applicable and possible 
Name of applied risk of bias tool(s) (e.g. 
CASP) or grading system(s) (e.g. GRADE) 
GRADE (when applicable and possible) 
Systematic literature review is/can be 
outsourced by the NITAG or expert group 
No 
Evidence assessment required to be 
performed 
Not applicable 
Contract allows sharing of systematic 
review with other parties 
Not applicable 
Systematic literature reviews conducted or 
published by others (e.g. Cochrane 
Collaboration) are/can be considered by 
NITAG or expert group/Executive 
Secretariat 
Yes 
Methodological quality of the review 
assessed by NITAG or expert 
group/Executive Secretariat using 
tool/assessment system 
Yes 
Name of tool(s) (e.g. AMSTAR) AMSTAR 
Mathematical modelling (e.g. transmission modelling) 
Recommendation development process 
includes consideration of results from 
mathematical modelling 
Yes – if available 
Developed by Outsourced 
Experience with adopting existing models 
from other countries to own setting 
Not applicable 
Health economic evaluations (e.g. cost-effectiveness studies) 
Recommendation development process 
includes consideration of results from 
health economic evaluations 
Yes 












Vaccine recommendation process 
Cost-effectiveness threshold (e.g. per 
QALY) 
Not applicable 
Cost-effectiveness threshold definite 
criterion for/against vaccine introduction 
Not applicable 
Tender system in place  Yes 
National/regional/local Regional and local  
Decision communication 
Rationale for vaccine recommendation 
published 
Yes 
Rationale includes Narrative summary 
References of used literature 














UNITED KINGDOM (validated)  As of 30 April 2014 
General facts 
Name of recommending body Joint Committee on Vaccination and Immunisation (JCVI) 
Self-designation as National Immunisation 
Technical Advisory Group (NITAG) 
Yes 
Contact Joint Committee on Vaccination and Immunisation 
Year established 1963 
Website https://www.gov.uk/government/policy-advisory-groups/joint-committee-on-
vaccination-and-immunisation  
Website material in English Yes 
NITAG or /expert group executive 
secretariat/administrative office 
Yes 
NITAG or expert group receives 
(additional) scientific support from: 
Public Health England, commissioned academic groups 
Number of NITAG or expert group 
members 
18-20 
NITAG or expert group chair is 
elected/appointed by 
Department of Health (= Ministry of Health) 
Voting-member composition Clinicians, epidemiologists, health economists, immunologists, paediatricians, 
public health experts, social scientists, vaccinology experts, 
virologists/microbiologists, lay members 
Voting member(s) from Ministry of Health No 
Declaration of conflict of interest Yes 
Number of meetings per year 3 (of the main committee plus subcommittee meetings as necessary) 
Meetings open to public No 
Minutes published online Yes 
NITAG or expert group advises Department of Health (= Ministry of Health) 
Final decision-maker for vaccine 
introduction in the national programme 
The Minister of Health is obliged to introduce the vaccine if it is recommended by 
the JCVI and is cost-effective  
Funding scheme for vaccinations in the 
national immunisation schedule 
Tax-funded 
 
Vaccine recommendation process 
Systematic approach 
NITAG or expert group uses systematic 
approach for the development of national 
vaccine recommendations  
Yes 
Key elements of the systematic approach • Case of need 
• Efficacy 
• Effectiveness 
• Safety data 
• Cost-effectiveness 
Fixed list of key criteria which need to be 
addressed during  the development 
process  
No 
List of criteria Not applicable 
Systematic approach published Yes 
URL https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/224
864/JCVI_Code_of_Practice_revision_2013_-_final.pdf  
Systematic literature review 
Recommendation development process 
requires systematic literature review  
No 
Systematic literature review is conducted 
by the NITAG or expert group/Executive 
Secretariat itself 
No (but can be if sufficient resources) 
Data source(s) Not applicable 
Evidence assessment performed with 
tool/system 
Not applicable 
Name of applied risk of bias tool(s) (e.g. 
CASP) or grading system(s) (e.g. GRADE) 
Not applicable 
Systematic literature review is/can be 
outsourced by the NITAG or expert group 
Yes 
Evidence assessment required to be 
performed 
Process in development 
Contract allows sharing of systematic 
review with other parties 












Vaccine recommendation process 
Systematic literature reviews conducted or 
published by others (e.g. Cochrane 
Collaboration) are/can be considered by 
NITAG or expert group/Executive 
Secretariat 
Yes 
Methodological quality of the review 
assessed by NITAG or expert 
group/Executive Secretariat using 
tool/assessment system 
No 
Name of tool(s) (e.g. AMSTAR) Not applicable 
Mathematical modelling (e.g. transmission modelling) 
Recommendation development process 
includes consideration of results from 
mathematical modelling 
Yes 
Developed by Outsourced 
Experience with adopting existing models 
from other countries to own setting 
Not applicable 
Health economic evaluations (e.g. cost-effectiveness studies) 
Recommendation development process 
includes consideration of results from 
health economic evaluations 
Yes 
Contains cost-effectiveness threshold Yes 
Cost-effectiveness threshold (e.g. per 
QALY) 
GBP 20 000 to GBP 30 000/QALY 
Cost-effectiveness threshold definite 
criterion for/against vaccine introduction 
Yes 
Tender system in place  Yes  
National/regional/local National 
Decision communication 
Rationale for vaccine recommendation 
published 
Yes 
Rationale includes Narrative summary 














Appendix C. List of studies excluded from the 
systematic literature review 
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groups outside of Europe/North America, or WHO SAGE. 
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